<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas - Abdel‐Rahman, O - 2018 | Cochrane Library</title> <meta content="Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas - Abdel‐Rahman, O - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011746.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas - Abdel‐Rahman, O - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011746.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011746.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas" name="citation_title"/> <meta content="Omar Abdel‐Rahman" name="citation_author"/> <meta content="omar.abdelrhman@med.asu.edu.eg" name="citation_author_email"/> <meta content="Zeinab Elsayed" name="citation_author"/> <meta content="Faculty of Medicine, Ain Shams University" name="citation_author_institution"/> <meta content="Hesham Elhalawani" name="citation_author"/> <meta content="The University of Texas MD Anderson Cancer Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD011746.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011746.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011746.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011746.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Ampulla of Vater; Antimetabolites, Antineoplastic [adverse effects, *therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Biliary Tract Neoplasms [*drug therapy, mortality, pathology]; Capecitabine [administration &amp; dosage, adverse effects]; Cholangiocarcinoma [*drug therapy, mortality, pathology]; Cisplatin [administration &amp; dosage, adverse effects]; Deoxycytidine [adverse effects, *analogs &amp; derivatives, therapeutic use]; Drug Combinations; Gallbladder Neoplasms [drug therapy, mortality, pathology]; Gemcitabine; Mitomycin [administration &amp; dosage, adverse effects]; Organoplatinum Compounds [administration &amp; dosage, adverse effects]; Oxaliplatin; Oxonic Acid [administration &amp; dosage, adverse effects]; Piperidines [administration &amp; dosage, adverse effects]; Quinazolines [administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Tegafur [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011746.pub2&amp;doi=10.1002/14651858.CD011746.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011746\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011746\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","zh_HANS","fa","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011746.pub2",title:"Gemcitabine\\u2010based chemotherapy for advanced biliary tract carcinomas",firstPublishedDate:"Apr 6, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011746.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011746.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011746.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011746.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011746.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011746.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011746.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011746.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011746.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011746.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4747 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011746.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0147"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-sec-0141"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/appendices#CD011746-sec-0152"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/table_n/CD011746StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/table_n/CD011746StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#CD011746-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Omar Abdel‐Rahman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#CD011746-cr-0003">Zeinab Elsayed</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information#CD011746-cr-0004">Hesham Elhalawani</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information/en#CD011746-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011746.pub2">https://doi.org/10.1002/14651858.CD011746.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011746-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011746-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011746-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011746-abs-0001" lang="en"> <section id="CD011746-sec-0001"> <h3 class="title" id="CD011746-sec-0001">Background</h3> <p>Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocarcinomas, gallbladder carcinomas, and ampullary carcinomas. Surgery remains the optimal modality of therapy leading to long‐term survival for people diagnosed with resectable biliary tract carcinomas. Unfortunately, most people with biliary tract carcinomas are diagnosed with either unresectable locally‐advanced or metastatic disease, and they are only suitable for palliative chemotherapy or supportive care. </p> </section> <section id="CD011746-sec-0002"> <h3 class="title" id="CD011746-sec-0002">Objectives</h3> <p>To assess the benefits and harms of intravenous administration of gemcitabine monotherapy or gemcitabine‐based chemotherapy versus placebo, or no intervention, or other treatments (excluding gemcitabine) in adults with advanced biliary tract carcinomas. </p> </section> <section id="CD011746-sec-0003"> <h3 class="title" id="CD011746-sec-0003">Search methods</h3> <p>We performed electronic searches in the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded, and Conference Proceedings Citation Index – Science up to June 2017. We also checked reference lists of primary original studies and review articles manually, for further related articles (cross‐references). </p> </section> <section id="CD011746-sec-0004"> <h3 class="title" id="CD011746-sec-0004">Selection criteria</h3> <p>Eligible studies include randomised clinical trials, irrespective of language or publication status, comparing intravenous administration of gemcitabine monotherapy or gemcitabine‐based combination to placebo, to no intervention, or to treatments other than gemcitabine. </p> </section> <section id="CD011746-sec-0005"> <h3 class="title" id="CD011746-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We assessed risks of bias of the included trials using definitions of predefined bias risk domains, and presented the review results incorporating the methodological quality of the trials using GRADE. </p> </section> <section id="CD011746-sec-0006"> <h3 class="title" id="CD011746-sec-0006">Main results</h3> <p>We included seven published randomised clinical trials with 600 participants. All included trials were at high risk of bias, and we rated the evidence as very low quality. Cointerventions were equally applied in three trials (gemcitabine plus S‐1 (a combination of tegafur, gimeracil, and oteracil) versus S‐1 monotherapy; gemcitabine plus S‐1 versus gemcitabine monotherapy versus S‐1 monotherapy; and gemcitabine plus vandetanib versus gemcitabine plus placebo versus vandetanib monotherapy), while four trials compared gemcitabine plus cisplatin versus S‐1 plus cisplatin; gemcitabine plus mitomycin C versus capecitabine plus mitomycin C; gemcitabine plus oxaliplatin versus chemoradiotherapy; and gemcitabine plus oxaliplatin versus 5‐fluorouracil plus folinic acid versus best supportive care. The seven trials were conducted in India, Japan, France, China, Austria, South Korea, and Italy. The median age of the participants in the seven trials was between 50 and 60 years, and the male/female ratios were comparable in most of the trials. Based on these seven trials, we established eight comparisons. We could not perform all planned analyses in all comparisons because of insufficient data. </p> <p><b>Gemcitabine versus vandetanib</b><br/> One three‐arm trial compared gemcitabine versus vandetanib versus both drugs in combination. It reported no data for mortality, health‐related quality of life, or tumour progression outcomes. We rated the increased risk of serious adverse events, anaemia, and overall response rate as very low‐certainty evidence. </p> <p><b>Gemcitabine plus cisplatin versus S‐1 plus cisplatin</b><br/> From one trial of 96 participants, we found very low‐certainty evidence that gemcitabine can lower the risk of mortality at one year when used with cisplatin versus S‐1 plus cisplatin (risk ratio (RR) 0.76, 95% confidence interval (CI) 0.58 to 0.98; P = 0.04; participants = 96). The trial did not report data for serious adverse events, quality of life, or tumour response outcomes. There is very low‐certainty evidence that gemcitabine plus cisplatin combination leads to a higher risk of high‐grade thrombocytopenia compared with S‐1 plus cisplatin combination (RR 5.28, 95% CI 1.23 to 22.55; P = 0.02; participants = 96). </p> <p><b>Gemcitabine plus S‐1 versus S‐1</b><br/> From two trials enrolling 151 participants, we found no difference between the two groups in terms of risk of mortality at one year or risk of serious adverse events. Gemcitabine plus S‐1 combination was associated with a higher overall response rate compared with S‐1 alone (RR 2.46, 95% CI 1.27 to 4.75; P = 0.007; participants = 140; trials = 2; I<sup>2</sup> = 0%; very low certainty of evidence). Neither of the trials reported data for health‐related quality of life or time to progression of the tumour. </p> <p><b>Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus folinic acid versus best supportive care</b><br/> One three‐arm trial compared gemcitabine plus oxaliplatin versus 5‐fluorouracil plus folinic acid versus best supportive care. It reported no data for serious adverse events, health‐related quality of life, or tumour progression. We rated the evidence for mortality and for overall response rate as of very low certainty. </p> <p><b>Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy</b><br/> One trial of 34 participants compared gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy. It reported no data for quality of life, overall response rate, or tumour progression outcomes. We rated the evidence for mortality and serious adverse events as of very low certainty. </p> <p><b>Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C</b><br/> One trial of 51 participants compared gemcitabine plus mitomycin C versus capecitabine plus mitomycin C. It reported no data for serious adverse events, quality of life, or tumour progression. We rated the evidence for mortality, overall response rate and thrombocytopenia as of very low certainty. </p> <p>We also identified three ongoing trials evaluating outcomes of interest for our review, which we can incorporate in future updates. </p> <p>For‐profit bias: there was a high risk of for‐profit bias in two trials (because of industry sponsorship) while there was a low risk of for‐profit bias in another three trials, and unclear risk in two trials. </p> </section> <section id="CD011746-sec-0007"> <h3 class="title" id="CD011746-sec-0007">Authors' conclusions</h3> <p>In adults with advanced biliary tract carcinomas, the effects of gemcitabine or gemcitabine‐based chemotherapy are uncertain on mortality and overall response compared with a range of inactive or active controls. The very low certainty of evidence is due to risk of bias, lack of information in the analyses and hence large imprecision, and possible publication bias. The confidence intervals do not rule out meaningful benefits or lack of effect of gemcitabine in all comparisons but one on mortality where gemcitabine plus cisplatin is compared with S‐1 plus cisplatin. Gemcitabine‐based regimens showed an increase in non‐serious adverse events (particularly haematological toxicities). Further randomised clinical trials are mandatory, to further explore the best therapeutic options for adults with advanced biliary tract carcinomas. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011746-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011746-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011746-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ro#CD011746-abs-0011">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011746-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011746-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011746-abs-0003" lang="en"> <h3>Gemcitabine‐containing chemotherapy for people with advanced bile duct cancer</h3> <p><b>Review question</b> </p> <p>What are the benefits and harms of gemcitabine‐based chemotherapy versus placebo or no intervention or gemcitabine‐based chemotherapy versus chemotherapy without gemcitabine in people with advanced bile duct cancer? </p> <p><b>Background</b><br/> Bile duct cancer (starting in the bile duct) is an uncommon malignant tumour. In most people, bile duct cancer is diagnosed at an advanced stage. For them, treatment options include drugs (chemotherapy). Gemcitabine is a drug used to treat certain types of cancerous tumours, including advanced bile duct cancer. Gemcitabine is an active chemotherapy drug, and in combination with cisplatin has been the accepted standard treatment in this disease. </p> <p><b>Study characteristics</b> </p> <p>The review authors searched published medical articles to clarify the role of gemcitabine (given by injection into a vein) compared with placebo (an inactive substance or preparation used as a control intervention in an experiment), or with no intervention, or with non‐gemcitabine chemotherapy combinations in the treatment of people with advanced bile duct cancer. The review authors looked for randomised clinical trials, where people were allocated at random to one of two or more treatments groups, in order to perform statistical analysis from which to draw conclusions about the intervention. The evidence is current to June 2017. </p> <p><b>Key results</b> </p> <p>The review authors found seven randomised clinical trials, and judged all of them to be at high risk of bias. These trials randomised 600 people with advanced bile duct cancer. The majority of these trials suggested that there were no demonstrable differences in either benefits or harms between gemcitabine‐containing chemotherapy regimens compared with non‐gemcitabine chemotherapy combinations. Only one trial, comparing gemcitabine plus cisplatin versus S‐1 plus cisplatin suggested that gemcitabine‐containing regimens might decrease death. The review authors identified three ongoing randomised clinical trials. </p> <p>As far as funding goes, two of the seven trials were sponsored by the pharmaceutical industry, three were not sponsored by the industry, and the remaining two trials provided no information about funding. </p> <p><b>Quality of the evidence and conclusions</b> </p> <p>The evidence obtained from the seven low‐quality randomised trials was insufficient to prove whether or not gemcitabine‐containing combinations are better than non‐gemcitabine‐containing combinations for people with advanced bile duct cancer. Moreover, gemcitabine‐based combinations showed an increase in non‐serious adverse events, particularly haematological toxicities (damage to blood and body tissues). More randomised clinical trials are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011746-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-sec-0147">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-sec-0210">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011746-sec-0147"></div> <h3 class="title" id="CD011746-sec-0148">Implications for practice</h3> <section id="CD011746-sec-0148"> <p>In adults with advanced biliary tract carcinomas, the effects of gemcitabine or gemcitabine‐based chemotherapy are uncertain on mortality and on overall response, compared with a range of inactive or active controls. The very low certainty of evidence is due to risks of bias, lack of information in the analyses and hence large imprecision, and possible publication bias. The confidence intervals exclude neither meaningful benefits nor lack of effect in all comparisons but one on mortality where gemcitabine plus cisplatin is compared with S‐1 plus cisplatin. Gemcitabine‐based regimens showed an increase in non‐serious adverse events (particularly haematological toxicities). </p> </section> <h3 class="title" id="CD011746-sec-0149">Implications for research</h3> <section id="CD011746-sec-0149"> <p>There is a need for large, high‐quality randomised clinical trials of gemcitabine‐ and non‐gemcitabine‐based systemic therapy regimens for people with advanced biliary tract carcinomas. It is also important that the randomisation process is clearly described, as well as the interventions. The participant flow and data handling should be well specified. The trials must be designed and described following the SPIRIT statement (Standard Protocol Items: Recommendations for Interventional Trials; <a href="http://www.spirit-statement.org/" target="_blank">www.spirit‐statement.org/</a>) and the CONSORT statement (Consolidated Standards of Reporting Trials: <a href="http://www.consort-statement.org/" target="_blank">www.consort‐statement.org</a>). </p> <p>There is also a particular need for properly‐conducted placebo‐controlled randomised clinical trials, in order to provide better assessment of clinically‐important outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011746-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011746-sec-0029"></div> <div class="table" id="CD011746-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus vandetanib<br/> <b>Comparison:</b> vandetanib </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vandetanib</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus vandetanib</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.52 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000<br/> (141 to 472) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.40<br/> (1.25 to 23.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>113<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/> (45 to 832) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.12<br/> (0.90 to 56.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000<br/> (15 to 951) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gemcitabine versus vandetanib for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gemcitabine compared with vandetanib for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals </p> <p><b>Intervention:</b> gemcitabine </p> <p><b>Comparison:</b> vandetanib </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vandetanib</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000<br/> (111 to 412) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (0.41 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helath‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/> (29 to 619) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.77 (0.82 to 17.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>125 per 1000</p> <p>(16 to 984)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.38 (0.94 to 58.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus cisplatin<br/> <b>Comparison:</b> S‐1 plus cisplatin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with S‐1 plus cisplatin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus cisplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/> (0.58 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>614 per 1000<br/> (469 to 792) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.37 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/> (88 to 433) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.27<br/> (4.41 to 28.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>959 per 1000<br/> (375 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus S‐1<br/> <b>Comparison:</b> S‐1 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with S‐1</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus S‐1</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.33 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>431 per 1000<br/> (233 to 799) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.15 to 7.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/> (7 to 309) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (1.27 to 4.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not supported by Trial Sequential Analysis</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000<br/> (179 to 669) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/> (1.00 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000<br/> (480 to 763) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (two trials) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> best supportive care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with best supportive care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.53 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/> (471 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 34.00<br/> (2.11 to 547.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus oxaliplatin compared with fluorouracil plus folinic acid for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> fluorouracil plus folinic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fluorouracil plus folinic acid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.55 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>857 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>694 per 1000<br/> (471 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helath‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.15<br/> (0.64 to 7.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000<br/> (91 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus oxaliplatin compared with fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> fluorouracil plus cisplatin plus radiotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fluorouracil and cisplatin plus radiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.21 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<br/> (93 to 676) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.66 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/> (220 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011746-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus mitomycin C compared with mitomycin C plus capecitabine for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus mitomycin C<br/> <b>Comparison:</b> capecitabine plus mitomycin C </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with capecitabine plus mitomycin C</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus mitomycin C</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.89 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>769 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>877 per 1000<br/> (685 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/> (0.25 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000<br/> (77 to 529) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.29 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000<br/> (181 to 663) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011746-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-sec-0164">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011746-sec-0030"></div> <section id="CD011746-sec-0031"> <h3 class="title" id="CD011746-sec-0031">Description of the condition</h3> <p>Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocarcinomas, gallbladder carcinomas, and ampullary carcinomas (<a href="./references#CD011746-bbs2-0033" title="DeGroenPC , GoresGJ , LarussoNF , GundersonLL , NagorneyDM . Biliary tract cancers. New England Journal of Medicine1999;341(18):1368‐78. ">De Groen 1999</a>). Although these malignancies are anatomically related and have similar metastatic patterns, each has a distinct clinical presentation, molecular pathology, and prognosis (<a href="./references#CD011746-bbs2-0106" title="ZhuAX , HongTS , HezelAF , KoobyDA . Current management of gallbladder carcinoma. Oncologist2010;15(2):168‐81. ">Zhu 2010</a>; <a href="./references#CD011746-bbs2-0074" title="NakanumaY , KakudaY . Pathologic classification of cholangiocarcinoma: new concepts. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):277‐93. ">Nakanuma 2015</a>; <a href="./references#CD011746-bbs2-0060" title="JainA , KwongLN , JavleM . Genomic profiling of biliary tract cancers and implications for clinical practice. Current Treatment Options in Oncology2016;17(11):58. ">Jain 2016</a>). </p> <p>The incidence and mortality rates of biliary tract cancers has changed in the world since the mid‐1980s. Population‐based data from the Surveillance Epidemiology and End Results (SEER) Program showed an increase in the incidence and mortality of intrahepatic cholangiocarcinoma in the USA (<a href="./references#CD011746-bbs2-0078" title="PatelT . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (Baltimore, Md.)2001;33(6):1353‐7. ">Patel 2001</a>; <a href="./references#CD011746-bbs2-0088" title="ShaibYH , DavilaJA , McGlynnK , El‐SeragHB . Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. Journal of Hepatology2004;40(3):472‐7. ">Shaib 2004</a>; <a href="./references#CD011746-bbs2-0098" title="WelzelTM , McGlynnKA , HsingAW , O'BrienTR , PfeifferRM . Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra‐ and extrahepatic cholangiocarcinoma in the United States. Journal of National Cancer Institute2006;98(12):873‐5. ">Welzel 2006</a>). Similar trends were also observed in the UK between 1971 and 2001. In the British population, a 12‐fold increase in the incidence of intrahepatic cholangiocarcinoma and a marked decrease in the incidence of gallbladder carcinoma and extrahepatic cholangiocarcinoma were observed during this period (<a href="./references#CD011746-bbs2-0099" title="WestJ , WoodH , LoganRF , QuinnM , AithalGP . Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971‐2001. British Journal of Cancer2001;94(11):1751‐8. ">West 2001</a>). Consistent with these trends, there was a global trend of an increasing mortality from intrahepatic cholangiocarcinoma and decreasing mortality from extrahepatic cholangiocarcinoma, in industrialised countries and in low‐income countries (<a href="./references#CD011746-bbs2-0079" title="PatelT . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer2002;2:10. ">Patel 2002</a>). </p> <p>Gallbladder carcinoma is the most common and most aggressive cancer of the biliary tract. Worldwide, there is a prominent geographic variability in gallbladder carcinoma incidence that correlates with the prevalence of gallbladder stones. High incidences of gallbladder carcinoma are seen in South American countries, particularly Chile, Bolivia, and Ecuador, as well as some areas of India, Pakistan, Japan, and Korea (<a href="./references#CD011746-bbs2-0089" title="StromBL , SolowayRD , Rios‐DalenzJL , Rodriguez‐MartinezHA , WestSL , KinmanJL , et al. Risk factors for gallbladder cancer. An international collaborative case‐control study. Cancer1995;76(10):1747‐56. ">Strom 1995</a>; <a href="./references#CD011746-bbs2-0081" title="RandiG , FranceschiS , LaVecchiaC . Gallbladder cancer worldwide: geographical distribution and risk factors. International Journal of Cancer2006;118(7):1591‐602. ">Randi 2006</a>). Conditions that are associated with chronic inflammation of the gallbladder are considered risk factors for gallbladder carcinoma. These include gallstone disease, porcelain gallbladder, gallbladder polyps, chronic Salmonella infection, congenital biliary cysts, and abnormal pancreaticobiliary duct junction (<a href="./references#CD011746-bbs2-0106" title="ZhuAX , HongTS , HezelAF , KoobyDA . Current management of gallbladder carcinoma. Oncologist2010;15(2):168‐81. ">Zhu 2010</a>). </p> <p>Cholangiocarcinoma accounts for only 3% of all gastrointestinal carcinomas (<a href="./references#CD011746-bbs2-0097" title="VenookA . Treatment options for advanced biliary tract cancers. 10th Annual Clinical Cancer Update Course, Lake Tahoe, CA January 28‐29, 2011. ">Venook 2011</a>). Population‐based incidence data on cholangiocarcinoma are scanty and most cancer registries combine people with cholangiocarcinoma with people with other hepatobiliary malignancies, such as hepatocellular cancer and gallbladder carcinoma (<a href="./references#CD011746-bbs2-0079" title="PatelT . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer2002;2:10. ">Patel 2002</a>; <a href="./references#CD011746-bbs2-0062" title="KhanSA , ToledanoMB , Taylor‐RobinsonSD . Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2008;10(2):77‐82. ">Khan 2008</a>). Although there are many established risk factors for cholangiocarcinoma including parasitic infections, primary sclerosing cholangitis, biliary‐duct cysts, hepatolithiasis, toxins, and hepatitis viruses‐related cirrhosis (for intrahepatic cholangiocarcinoma) (<a href="./references#CD011746-bbs2-0095" title="TysonBL , El‐SeragBH . Risk factors of cholangiocarcinoma. Hepatology (Baltimore, Md.)2011;54(1):173‐84. ">Tyson 2011</a>), in most people with cholangiocarcinoma no predisposing factor is identified (<a href="./references#CD011746-bbs2-0030" title="ChapmanRW . Risk factors for biliary tract carcinogenesis. Annals of Oncology1999;10(Suppl 4):308‐11. ">Chapman 1999</a>). The prognosis of cholangiocarcinoma is poor, and incidence and mortality are almost similar (<a href="./references#CD011746-bbs2-0095" title="TysonBL , El‐SeragBH . Risk factors of cholangiocarcinoma. Hepatology (Baltimore, Md.)2011;54(1):173‐84. ">Tyson 2011</a>). </p> <p>The ampulla of Vater consists of the terminal portion of the common bile duct and main pancreatic duct, as well as a small segment of the duodenal mucosa (<a href="./references#CD011746-bbs2-0100" title="WestgaardA , TafjordS , FarstadIN , CvancarovaM , EideTJ , MathisenO , et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer2008;8:170. ">Westgaard 2008</a>). Because of its small size, adenocarcinomas are relatively uncommon in comparison with those arising in the pancreas or common bile duct. They account for only 0.5% of all gastrointestinal malignancies, and cancers of the ampulla of Vater are usually reported in case‐controlled studies from single or collaborating institutions (<a href="./references#CD011746-bbs2-0024" title="Albores‐SaavedraJ , SchwartzAM , BatichK , HensonDE . Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. Journal of Surgical Oncology2009;100(7):598‐605. ">Albores‐Saavedra 2009</a>). Although ampullary carcinomas are classified among biliary tract carcinomas, they are biologically and clinically distinct for their pathological, prognostic, and therapeutic features, and so the interpretation of study results in this specific patient subgroup have to be made cautiously. </p> <p>Surgery remains the optimal modality of therapy leading to long‐term survival for people diagnosed with resectable biliary tract carcinomas. Unfortunately, most people with biliary tract carcinomas are diagnosed with either unresectable locally‐advanced (stage III) or metastatic (stage IV) disease, and they are only suitable for palliative chemotherapy or supportive care (<a href="./references#CD011746-bbs2-0065" title="LamarcaA , HubnerRA , David RyderW , ValleJW . Second‐line chemotherapy in advanced biliary cancer: a systematic review. Annals of Oncology2014;25(12):2328‐38. ">Lamarca 2014</a>). The prognosis for such people is generally poor, resulting in a five‐year survival of 5% to 15% (<a href="./references#CD011746-bbs2-0025" title="AndersonCD , PinsonCW , BerlinJ , ChariRS . Diagnosis and treatment of cholangiocarcinoma. Oncologist2004;9(1):43‐57. ">Anderson 2004;</a><a href="./references#CD011746-bbs2-0035" title="DeOliveiraML , CunninghamSC , CameronJL , KamangarF , WinterJM , LillemoeKD , et al. Cholangiocarcinoma: thirty‐one‐year experience with 564 patients at a single institution. Annals of Surgery2007;245(5):755‐62. ">DeOliveira 2007</a>). </p> </section> <section id="CD011746-sec-0032"> <h3 class="title" id="CD011746-sec-0032">Description of the intervention</h3> <p>Chemotherapeutic agents have been studied extensively in advanced biliary carcinomas. Gemcitabine, either as a single agent or in combination with other chemotherapeutic agents, has been extensively evaluated in several phase II studies in people with advanced biliary tract carcinomas (<a href="./references#CD011746-bbs2-0041" title="GebbiaV , GiulianiF , MaielloE , ColucciG , VerderameF , BorsellinoN , et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single‐agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. Journal of Clinical Oncology2001;19(20):4089‐91. ">Gebbia 2001</a>; <a href="./references#CD011746-bbs2-0064" title="KubickaS , RudolphKL , TietzeMK , LorenzM , MannsM . Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato‐gastroenterology2001;48(39):783‐9. ">Kubicka 2001</a>; <a href="./references#CD011746-bbs2-0080" title="PenzM , KornekGV , RadererM , Ulrich‐PurH , FiebigerW , LenauerA , et al. Phase II trial of two‐weekly gemcitabine in patients with advanced biliary tract cancer. Annals of Oncology2001;12(2):183‐6. ">Penz 2001</a>). Overall, objective response with gemcitabine alone ranges from 7% to 27%, but median survival is only rarely longer than eight months (<a href="./references#CD011746-bbs2-0076" title="ParkJS , OhSY , KimSH , KwonHC , KimJS , Jin‐KimH , et al. Single‐agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japanese Journal of Clinical Oncology2005;35(2):68‐73. ">Park 2005</a>; <a href="./references#CD011746-bbs2-0090" title="SuzukiE , FuruseJ , IkedaM , OkusakaT , NakachiK , MitsunagaS , et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology2010;79(1‐2):39‐45. ">Suzuki 2010</a>). One retrospective study of 304 people with unresectable biliary tract carcinoma compared the outcome for people who received gemcitabine alone to people who received a cisplatin‐based regimen, a fluoropyrimidine‐based regimen, or best supportive care. Gemcitabine seemed to be the most effective treatment, with a reduction in mortality of about 50% when compared with best supportive care (<a href="./references#CD011746-bbs2-0105" title="YonemotoN , FuruseJ , OkusakaT , YamaoK , FunakoshiA , OhkawaS , et al. A multi‐center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese Journal of Clinical Oncology2007;37(11):843‐51. ">Yonemoto 2007</a>). The results of a pooled analysis of 104 trials that included 2810 people with advanced biliary tract carcinoma showed that response and tumour control were higher for the subgroup of people who received gemcitabine and platinum‐based agents. However, this tumour response did not translate into significant benefit in terms of either time to tumour progression or median overall survival (<a href="./references#CD011746-bbs2-0037" title="EckelF , SchmidRM . Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer2007;96(6):896‐902. ">Eckel 2007</a>; <a href="./references#CD011746-bbs2-0038" title="EckelF , SchmidRM . Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Chemotherapy2014;60(1):13‐23. ">Eckel 2014</a>). </p> <p>The superiority of gemcitabine plus cisplatin over gemcitabine alone was shown in the randomised clinical phase III multicentre ABC‐02 trial, which enrolled 410 people with locally‐advanced or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma. Participants were randomly assigned to six courses of cisplatin (25 mg/m<sup>2</sup>) followed by gemcitabine (1000 mg/m<sup>2</sup>) on days one and eight, every 21 days, versus gemcitabine alone (1000 mg/m<sup>2</sup> on days one, eight, and 15 every 28 days). At a median follow‐up of 8.2 months, overall survival was significantly longer with gemcitabine plus cisplatin therapy (11.7 months with gemcitabine plus cisplatin versus 8.1 months gemcitabine alone), as well as median progression‐free survival (eight months with gemcitabine plus cisplatin versus five months with gemcitabine alone). The proportion of participants with neutropenia was higher in the group receiving gemcitabine plus cisplatin. However, there was no significant difference in the proportion with neutropenia‐associated infections between the two treatment groups (<a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>; <a href="./references#CD011746-bbs2-0096" title="ValleJW , FuruseJ , JitlalM , BeareS , MizunoN , WasanH , et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta‐analysis of two randomised trials. Annals of Oncology2014;25(2):391‐8. ">Valle 2014</a>). Another smaller randomised clinical trial with 84 people with advanced biliary tract carcinoma reported a similar conclusion with a significantly longer overall survival with cisplatin plus gemcitabine compared with gemcitabine alone (11.2 months with gemcitabine plus cisplatin versus 7.7 months with gemcitabine alone) (<a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>). Other treatments which have been evaluated (with gemcitabine or compared to gemcitabine‐based regimens) include other chemotherapeutics (e.g. cisplatin, carboplatin, fluoropyrimidines) and localised radiotherapy in combination with concurrent chemotherapy (for peoples with locally‐advanced disease) (<a href="./references#CD011746-bbs2-0031" title="ChenL , ChenC , YenY , TamKW . Chemotherapy for advanced biliary tract carcinoma: a meta‐analysis of randomized controlled trials. Medicine2016;95(33):e4584. ">Chen 2016</a>). Additionally, alternative therapeutic strategies besides systemic chemotherapy have been suggested, mainly for intrahepatic cholangiocarcinoma including intra‐arterial chemotherapy, radioembolisation, and immune therapy (<a href="./references#CD011746-bbs2-0087" title="SchweitzerN , VogelA . Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):345‐53. ">Schweitzer 2015</a>)<i>. T</i>here is as yet no level‐I evidence of a survival benefit for targeted therapy in advanced biliary tract carcinomas (<a href="./references#CD011746-bbs2-0031" title="ChenL , ChenC , YenY , TamKW . Chemotherapy for advanced biliary tract carcinoma: a meta‐analysis of randomized controlled trials. Medicine2016;95(33):e4584. ">Chen 2016</a>) </p> </section> <section id="CD011746-sec-0033"> <h3 class="title" id="CD011746-sec-0033">How the intervention might work</h3> <p>Gemcitabine is a cell‐cycle phase‐specific chemotherapeutic agent. It primarily kills cells undergoing deoxyribonucleic acid (DNA) synthesis (S‐phase) as well as blocking the progression of cells through the G1/S‐phase boundary. Gemcitabine is metabolised intracellularly to the active diphosphate and triphosphate nucleotides. The cytotoxic effect of gemcitabine is due to a combination of the two actions by the diphosphate and the triphosphate nucleotides leading to inhibition of DNA synthesis (<a href="./references#CD011746-bbs2-0071" title="MiniE , NobiliS , CaciagliB , LandiniI , MazzeiT . Cellular pharmacology of gemcitabine. Annals of Oncology2006;17(Suppl 5):v7‐v12. ">Mini 2006</a>). </p> <p>Gemcitabine has shown biological activities in a broad spectrum of solid tumours, including pancreatic cancers (<a href="./references#CD011746-bbs2-0029" title="BurrisHA3rd , MooreMJ , AndersenJ , GreenMR , RothenbergML , ModianoMR , et al. Improvements in survival and clinical benefit with gemcitabine as first‐line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology1997;15(6):2403‐13. ">Burris 1997</a>). Because the biliary tract shares a common embryological origin with the exocrine pancreas, gemcitabine was considered as a reasonable therapeutic agent to be evaluated for the treatment of biliary tract cancers (<a href="./references#CD011746-bbs2-0076" title="ParkJS , OhSY , KimSH , KwonHC , KimJS , Jin‐KimH , et al. Single‐agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japanese Journal of Clinical Oncology2005;35(2):68‐73. ">Park 2005</a>). </p> </section> <section id="CD011746-sec-0034"> <h3 class="title" id="CD011746-sec-0034">Why it is important to do this review</h3> <p>For advanced biliary tract carcinoma, systemic therapy is the mainstay of treatment for people who present with unresectable or metastatic disease. Progress has been made since the mid‐2000s to identify the most effective chemotherapy regimens, with the recent recommendation of the combination of gemcitabine plus cisplatin as the standard schedule. This is based on the results of the ABC‐02 trial (<a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>), and the identically‐designed Japanese trial (<a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>). Both trials demonstrated a significantly longer overall survival with gemcitabine plus cisplatin compared with gemcitabine alone. However, gemcitabine plus cisplatin has not been directly compared with other non‐gemcitabine‐containing chemotherapy combinations in phase III trials. Comprehension of the molecular basis of cholangiocarcinogenesis and tumour progression has led to the testing of other chemotherapies in people with biliary tract carcinomas, demonstrating promising results (<a href="./references#CD011746-bbs2-0070" title="MarinoD , LeoneF , CavalloniG , CagnazzoC , AgliettaM . Biliary tract carcinomas: from chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology2013;85(2):136‐48. ">Marino 2013</a>; <a href="./references#CD011746-bbs2-0087" title="SchweitzerN , VogelA . Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):345‐53. ">Schweitzer 2015</a>; <a href="./references#CD011746-bbs2-0031" title="ChenL , ChenC , YenY , TamKW . Chemotherapy for advanced biliary tract carcinoma: a meta‐analysis of randomized controlled trials. Medicine2016;95(33):e4584. ">Chen 2016</a>). Although gemcitabine plus cisplatin is considered a standard option for advanced biliary cancer, exploration of other systemic therapy regimens in people with advanced biliary tract carcinomas is still needed, in order to improve outcomes for this disease. Moreover, the population of biliary tract carcinomas is heterogeneous, and because the incidence of biliary tract carcinoma is low, people with unresectable, metastatic or recurrent cancers are often enrolled in the same randomised clinical trial. Thus, the efficacy of gemcitabine‐based chemotherapy in all clinical contexts and anatomical subsites needs detailed assessment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011746-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-sec-0169">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011746-sec-0035"></div> <p>To assess the benefits and harms of intravenous administration of gemcitabine monotherapy or gemcitabine‐based chemotherapy versus placebo, no intervention, or other treatments (excluding gemcitabine) in adults with advanced biliary tract carcinomas. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011746-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-sec-0170">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011746-sec-0036"></div> <section id="CD011746-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011746-sec-0038"> <h4 class="title">Types of studies</h4> <p>All randomised clinical trials, irrespective of language or publication status, comparing intravenous administration of gemcitabine monotherapy or gemcitabine‐based combination therapy compared to placebo, to no intervention, or to treatments other than gemcitabine. We examined non‐randomised studies retrieved with the searches for harmful effects only. We are aware that this may bias our review towards assessing benefits rather than harms. </p> </section> <section id="CD011746-sec-0039"> <h4 class="title">Types of participants</h4> <p>All chemotherapy‐naïve people with cytological or histopathological evidence of advanced (either unresectable or metastatic) biliary tract carcinomas (i.e. intra‐ and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma) who are without clinical evidence of active or former concurrent malignant diseases, and are older than 18 years. The definition of unresectable biliary tract carcinomas was according to the authors of the individual trials. </p> </section> <section id="CD011746-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Intravenous gemcitabine (monotherapy or combination therapy) versus placebo or no treatment, or treatments other than gemcitabine: </p> <p> <ul id="CD011746-list-0001"> <li> <p>gemcitabine‐based chemotherapy versus placebo or no intervention;</p> </li> <li> <p>gemcitabine‐based chemotherapy versus chemotherapy without gemcitabine.</p> </li> </ul> </p> </section> <section id="CD011746-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD011746-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011746-list-0002"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events. We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (<a href="./references#CD011746-bbs2-0059" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>); that is, any untoward medical occurrence that results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. We considered all other adverse events as non‐serious (see below). </p> </li> <li> <p>Health‐related quality of life: if reported in individual trials by the participants and if measured with validated instruments. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011746-list-0003"> <li> <p>Tumour response assessments (as recommended by the response evaluation in solid tumours criteria) using the following definitions of response (<a href="./references#CD011746-bbs2-0040" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228‐47. ">Eisenhauer 2009</a>): </p> <ul id="CD011746-list-0004"> <li> <p>complete response: disappearance of all target lesions. Any pathological lymph nodes (whether target or non‐target) must have reduction in short axis to less than 10 mm; </p> </li> <li> <p>partial response: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; </p> </li> <li> <p>progressive disease: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Note: the appearance of one or more new lesions is also considered progression; </p> </li> <li> <p>stable disease: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. </p> </li> </ul> </li> </ul> </p> <p>We combined complete response and partial response to evaluate the overall response rate. However, alternative criteria could have been added according to the choice of the trial authors. </p> <p> <ul id="CD011746-list-0005"> <li> <p>Time to progression of the tumour (reported as median time to progression).</p> </li> <li> <p>(Non‐serious) adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011746-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011746-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD011746-bbs2-0042" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2018, Issue 3. Art. No.: LIVER. ">Gluud 2018</a>; June 2017), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2017, Issue 5), MEDLINE Ovid (1946 to June 2017), Embase Ovid (1974 to June 2017), LILACS (Bireme; 1982 to June 2017), Science Citation Index Expanded (Web of Science; 1900 to June 2017), and Conference Proceedings Citation Index – Science (Web of Science; 1990 to June 2017) (<a href="./references#CD011746-bbs2-0083" title="RoyleP , MilneR . Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). <a href="./appendices#CD011746-sec-0153">Appendix 1</a> shows the search strategies used for the electronic searches. We also searched the <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> register for additional studies and for ongoing studies. We added these to <a href="./references#CD011746-sec-0163" title="">Characteristics of ongoing studies</a>. </p> </section> <section id="CD011746-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We manually checked reference lists of the included studies and review articles for more trials of interest (cross‐references). </p> </section> </section> <section id="CD011746-sec-0047"> <h3 class="title" id="CD011746-sec-0047">Data collection and analysis</h3> <p>We conducted the review according to recommendations of Cochrane (<a href="./references#CD011746-bbs2-0057" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD011746-bbs2-0042" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2018, Issue 3. Art. No.: LIVER. ">Gluud 2018</a>). We performed the analyses using Review Manager 5 (<a href="./references#CD011746-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD011746-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Independently of each other, we identified the trials for inclusion. We have listed the excluded studies with the reasons for exclusion. </p> <p>We excluded duplicate records based on consideration of titles and abstracts. We reviewed abstracts of the remaining articles. We conducted a review of the remaining articles for relevancy and reporting of outcomes of interest. </p> </section> <section id="CD011746-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We individually extracted the required data. We extracted details of study population, interventions, and outcomes using a standardised data extraction form. This form included the following items: </p> <p> <ul id="CD011746-list-0006"> <li> <p>publication year;</p> </li> <li> <p>country;</p> </li> <li> <p>year of conduct of the trial;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>sample size calculation performed or not;</p> </li> <li> <p>population characteristics, such as age and sex ratio;</p> </li> <li> <p>sample size reached or not;</p> </li> <li> <p>baseline characteristics including: Eastern Cooperative Oncology Group Performance Status; stage; and primary subsite of the tumour: intrahepatic and extrahepatic cholangiocarcinomas, gallbladder carcinomas, and ampullary carcinomas; </p> </li> <li> <p>outcomes (see <a href="#CD011746-sec-0042">Primary outcomes</a>; <a href="#CD011746-sec-0043">Secondary outcomes</a>); </p> </li> <li> <p>risk of bias (see <a href="#CD011746-sec-0050">Assessment of risk of bias in included studies</a>); </p> </li> <li> <p>intention‐to‐treat analysis.</p> </li> </ul> </p> </section> <section id="CD011746-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Due to the risk of overestimation of beneficial intervention effects and underestimation of harmful intervention effects in randomised clinical trials of unclear or inadequate methodological quality (<a href="./references#CD011746-bbs2-0086" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD011746-bbs2-0072" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD011746-bbs2-0063" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011746-bbs2-0104" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>; <a href="./references#CD011746-bbs2-0084" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savović 2012a</a>; <a href="./references#CD011746-bbs2-0085" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savović 2012b</a>; <a href="./references#CD011746-bbs2-0067" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>), we assessed the influence of the risks of bias on our results. We used the domains with definitions provided below to assess the risks of bias in the included trials (<a href="./references#CD011746-bbs2-0057" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD011746-bbs2-0042" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2018, Issue 3. Art. No.: LIVER. ">Gluud 2018</a>). In our assessment of the risks of bias, we included assessments of available information included in trial registrations unless the trial was registered after the trial was completed. </p> <section id="CD011746-sec-0051"> <h5 class="title">Allocation sequence generation (selection bias)</h5> <p> <ul id="CD011746-list-0007"> <li> <p>Low risk of bias: sequence generation was achieved using computer random‐number generation or a random‐number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random. We included such studies only for assessments of harms. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0052"> <h5 class="title">Allocation concealment (selection bias)</h5> <p> <ul id="CD011746-list-0008"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of or during enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially‐numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of or during enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. We included such studies only for assessments of harms. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0053"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p> <ul id="CD011746-list-0009"> <li> <p>Low risk of bias: it was mentioned that both the participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial. </p> </li> <li> <p>Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial. </p> </li> <li> <p>High risk of bias: the trial was not blinded, so that the allocation was known during the trial. We included such studies only for assessments of harms. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0054"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p> <ul id="CD011746-list-0010"> <li> <p>Low risk of bias: outcome assessment was carried out blinded for all relevant outcomes, and the method of blinding was described, so that knowledge of allocation was prevented. </p> </li> <li> <p>Unclear risk of bias: blinding of outcome assessment was not described, or the outcome assessment was described as blinded, but the method of blinding was not described, so that knowledge of allocation was possible. </p> </li> <li> <p>High risk of bias: outcome assessment was not blinded, so that the allocation was known to outcome assessors. We included such studies only for assessments of harms. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0055"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p> <ul id="CD011746-list-0011"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias in the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD011746-sec-0056"> <h5 class="title">Selective outcome reporting (reporting bias)</h5> <p> <ul id="CD011746-list-0012"> <li> <p>Low risk: the trial reported the following predefined outcomes: all‐cause mortality, serious adverse events, and tumour response (see <a href="#CD011746-sec-0043">Secondary outcomes</a>). When the original trial protocol was available, the outcomes were those called for in that protocol. When the trial protocol was obtained from a trial registry (e.g. <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), the outcomes sought were those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, we did not consider those outcomes to be reliable. </p> </li> <li> <p>Unclear risk: not all predefined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not. </p> </li> <li> <p>High risk: one or more predefined outcomes were not reported.</p> </li> </ul> </p> </section> <section id="CD011746-sec-0057"> <h5 class="title">For‐profit bias</h5> <p> <ul id="CD011746-list-0013"> <li> <p>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for‐profit support that may manipulate the trial design, conduct or results. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not be free of for‐profit bias, as no information on clinical trial support or sponsorship was provided. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </p> </section> <section id="CD011746-sec-0058"> <h5 class="title">Other bias</h5> <p> <ul id="CD011746-list-0014"> <li> <p>Low risk of bias: the trial appeared to be free of other factors that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias. We included such studies only for assessments of harms. </p> </li> </ul> </p> <p>We judged trials to be at low overall risk of bias if rated as low risk of bias in all the above domains. We judged trials to be at high overall risk of bias if rated as unclear risk of bias or high risk of bias in one or more of the above domains. </p> <p>We resolved any differences in opinion through discussion; in the case of unsettled disagreements, we planned to ask a member of the Cochrane Hepato‐Biliary Group Editorial Team Office to adjudicate. </p> </section> </section> <section id="CD011746-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables, we calculated the risk ratio (RR) with a 95% confidence interval (CI). For continuous variables, we planned to calculate the mean difference (MD) or standardised mean difference (SMD) with its 95% CI. Time‐to‐event data analyses are usually based on hazard ratios (HRs), so if these data were provided we planned to use the HR. If HR data were not provided, we planned to calculate the ln(HR) and its standard error indirectly, or we planned to use an Excel spreadsheet to obtain the exact HR (<a href="./references#CD011746-bbs2-0077" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>). </p> </section> <section id="CD011746-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis is the group of participants in each intervention group in the randomised clinical trials with a parallel‐group design. In the case of cross‐over trials, we used the data from the first trial period only. In case of trials with more than two intervention groups, we produced two different analyses, comparing the intervention group with the common control group. </p> </section> <section id="CD011746-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>When we could not extract data from the text, we contacted the authors of the original publication to ask for missing information. </p> <p><b>Intention‐to‐treat analyses</b> </p> <p>For the primary outcomes, we planned to include participants with incomplete or missing data in sensitivity analyses by imputing them according to the following scenarios (<a href="./references#CD011746-bbs2-0058" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.)1999;319(7211):670‐4. ">Hollis 1999</a>): </p> <p> <ul id="CD011746-list-0015"> <li> <p>Extreme case analysis favouring the experimental intervention ('best‐worse' case scenario): none of the dropouts/participants lost from the experimental group, but all of the dropouts/participants lost from the control group experienced the outcome; we included all randomised participants in the denominator; </p> </li> <li> <p>Extreme case analysis favouring the control ('worst‐best' case scenario): all dropouts/participants lost from the experimental group, but none from the control group experienced the outcome; we included all randomised participants in the denominator. </p> </li> </ul> </p> <p>However, because there was a low risk of attrition bias in most of the included trials, we did not do these analyses. </p> </section> <section id="CD011746-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi<sup>2</sup> test to provide an indication of between‐trial heterogeneity. In addition, we quantified the degree of heterogeneity observed in the results using the I<sup>2</sup> statistic, which can be interpreted as the percentage of variation observed between the trials attributable to between‐trial differences rather than sampling error (chance). </p> <p>We interpreted I<sup>2</sup> values as follows: </p> <p> <ul id="CD011746-list-0016"> <li> <p>probably not important: 0% to 40%;</p> </li> <li> <p>possible moderate heterogeneity: 30% to 60%;</p> </li> <li> <p>possible substantial heterogeneity: 50% to 90%;</p> </li> <li> <p>considerable heterogeneity: 75% to 100% (<a href="./references#CD011746-bbs2-0057" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </li> </ul> </p> </section> <section id="CD011746-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We carried out a comprehensive search in order to minimise the risk of publication bias. Because we did not identify enough trials for inclusion (10 trials), we did not use a funnel plot to explore bias (<a href="./references#CD011746-bbs2-0039" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315:629‐34. ">Egger 1997</a>; <a href="./references#CD011746-bbs2-0068" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. ">Macaskill 2001</a>). </p> </section> <section id="CD011746-sec-0064"> <h4 class="title">Data synthesis</h4> <p>The review authors followed the instructions given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011746-bbs2-0057" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD011746-bbs2-0042" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2018, Issue 3. Art. No.: LIVER. ">Gluud 2018</a>). </p> <section id="CD011746-sec-0065"> <h5 class="title">Meta‐analysis</h5> <p>We used random‐effects model (<a href="./references#CD011746-bbs2-0036" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and fixed‐effect model (<a href="./references#CD011746-bbs2-0069" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;2(4):719‐48. ">Mantel 1959</a>; <a href="./references#CD011746-bbs2-0034" title="DeMetsDL . Methods of combining randomised clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>) meta‐analyses. In case of discrepancy between the two models (e.g. one giving a significant intervention effect, and the other no significant intervention effect), we reported both results; otherwise, we reported only the results from the meta‐analysis model with the most conservative intervention effect (<a href="./references#CD011746-bbs2-0061" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>). </p> </section> <section id="CD011746-sec-0066"> <h5 class="title">Trial Sequential Analysis</h5> <p>We examined intervention effects with Trial Sequential Analysis (TSA) (<a href="./references#CD011746-bbs2-0093" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 21 February 2017). ">Thorlund 2011</a>; <a href="./references#CD011746-bbs2-0094" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>; <a href="./references#CD011746-bbs2-0103" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. ">Wetterslev 2017</a>), in order to evaluate if intervention effects could be caused by random error ('play of chance') (<a href="./references#CD011746-bbs2-0027" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD011746-bbs2-0101" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011746-bbs2-0028" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. ">Brok 2009</a>; <a href="./references#CD011746-bbs2-0091" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology2009;38(1):276‐86. ">Thorlund 2009</a>, <a href="./references#CD011746-bbs2-0102" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD011746-bbs2-0092" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). However, we found TSA only suitable for one comparison out of the seven comparisons of the review. </p> <p>We applied Trial Sequential Analysis as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD011746-bbs2-0101" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>). To control for random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect). The required information size calculation should also account for the diversity present in the meta‐analysis (<a href="./references#CD011746-bbs2-0102" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). In our meta‐analysis, the diversity‐adjusted required information size was based on the event proportion in the control group; assumption of a plausible risk ratio reduction of 20% or the risk ratio reduction observed in the included trials at low risk of bias; a risk of type I error of 2.5%, a risk of type II error of 10%, and the assumed diversity of the meta‐analysis. The underlying assumption of Trial Sequential Analysis is that testing for significance may be performed each time a new trial is added to the meta‐analysis. We added the trials according to the year of publication, and, if more than one trial was published in a year, we added trials alphabetically according to the last name of the first author. On the basis of the diversity‐adjusted required information size, we constructed trial sequential monitoring boundaries (<a href="./references#CD011746-bbs2-0101" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011746-bbs2-0093" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 21 February 2017). ">Thorlund 2011</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size; if the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit or harm before the diversity‐adjusted required information size is reached, firm evidence may perhaps be established and further trials may be superfluous. On the contrary, if the boundary is not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. That can be determined by assessing if the cumulative Z‐curve crosses the trial sequential monitoring boundaries for futility. </p> </section> </section> <section id="CD011746-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform a subgroup analysis comparing the intervention effect in:</p> <p> <ul id="CD011746-list-0017"> <li> <p>trials at low risk of bias compared to trials at high risk of bias;</p> </li> <li> <p>Eastern Cooperative Oncology Group Performance Score 0 compared to score 1 or 2;</p> </li> <li> <p>tumour site (cholangiocarcinoma, gallbladder carcinoma, ampullary carcinoma);</p> </li> <li> <p>tumour stage.</p> </li> </ul> </p> <p>However, because of insufficient trial data, we could not perform all these subgroup analyses. </p> </section> <section id="CD011746-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the robustness of the eligibility criteria, in addition to the sensitivity analyses specified under <a href="#CD011746-sec-0061">Dealing with missing data</a>, we planned to undertake sensitivity analyses that may explain our findings, including any observed heterogeneity. However, because of missing data, we could not perform this sensitivity analysis. </p> <section id="CD011746-sec-0069"> <h5 class="title">'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables using GRADEpro (<a href="./references#CD011746-bbs2-0043" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group 2004‐2007, 2008. ">GRADEpro 2008;</a><a href="#CD011746-tbl-0009">Table 1</a>). We used the GRADE approach which appraises the certainty of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The certainty of evidence considers within‐study risk of bias, indirectness of the evidence (population, intervention, control, outcomes), unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); imprecision of results (wide CIs as evaluated with Trial Sequential Analyses) (<a href="./references#CD011746-bbs2-0061" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014</a>), and risk of publication bias (<a href="./references#CD011746-bbs2-0026" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines 3: rating the quality of evidence ‐ introduction. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>; <a href="./references#CD011746-bbs2-0044" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011a</a>; <a href="./references#CD011746-bbs2-0045" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐‐ publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011b</a>; <a href="./references#CD011746-bbs2-0046" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011c</a>; <a href="./references#CD011746-bbs2-0047" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011d</a>; <a href="./references#CD011746-bbs2-0048" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011e</a>; <a href="./references#CD011746-bbs2-0049" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011f</a>; <a href="./references#CD011746-bbs2-0050" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011g</a>; <a href="./references#CD011746-bbs2-0051" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011h</a>; <a href="./references#CD011746-bbs2-0052" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [PUBMED: 22542023] ">Guyatt 2013a</a>; <a href="./references#CD011746-bbs2-0053" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [PUBMED: 22609141] ">Guyatt 2013b</a>; <a href="./references#CD011746-bbs2-0054" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173‐83. [PUBMED: 23116689] ">Guyatt 2013c</a>; <a href="./references#CD011746-bbs2-0055" title="GuyattG , AndrewsJ , OxmanAD , AldersonP , DahmP , Falck‐YtterY , et al. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology2013;66(7):719‐25. ">Guyatt 2013d</a>; <a href="./references#CD011746-bbs2-0073" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736‐42; quiz 742.e1‐5. [PUBMED: 23623694] ">Mustafa 2013</a>; <a href="./references#CD011746-bbs2-0056" title="GuyattGH , EbrahimS , Alonso‐CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines: 17. Assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14‐22. [PUBMED: 28529188] ">Guyatt 2017</a>). </p> <div class="table" id="CD011746-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Explanations for Cochrane 'Summary of findings' tables</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Examples from table</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The tables provide the findings for the most important outcomes for someone making a decision. These include potential benefits and harms, whether the included trials provide data for these outcomes or not. Additional findings may be reported elsewhere in the review. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed control group risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed control group risks can be based either on the control group risks reported in the included trials or on epidemiological data from elsewhere. When only one control group risk is provided, it is normally the median control group risk across the trials that provided data for that outcome. </p> <p>Risk is the probability of an outcome occurring. The control group risk is the risk of an outcome occurring in the comparison group (without the intervention). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corresponding intervention group risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk is the probability of an outcome occurring. The intervention group risk is the risk of an outcome occurring in the group receiving the intervention. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relative effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect or RR (risk ratio)</b> </p> <p>Relative effects are ratios. Here the relative effect is expressed as a risk ratio.</p> <p>Risk is the probability of an outcome occurring. An RR is the ratio between the risk in the intervention group and the risk in the control group. If the risk in the control group is 10% (100 per 1000) and the risk in the intervention group is 1% (10 per 1000), the RR is 10/100 or 0.10. </p> <p>If the RR is exactly 1.0, this means that there is no difference between the occurrence of the outcome in the intervention and the control group. It is unusual for the RR to be exactly 1.0, and understanding what it means if it is above or below this value depends on whether the outcome being counted is judged to be good or bad. </p> <p>If the RR is greater than 1.0, the intervention increases the risk of the outcome. If it is a good outcome (e.g. the birth of a healthy baby), an RR &gt; 1.0 indicates a desirable effect for the intervention, whereas if the outcome is bad (e.g. death), an RR &gt; 1.0 would indicate an undesirable effect. </p> <p>If the RR is less than 1.0, the intervention decreases the risk of the outcome. This indicates a desirable effect if it is a bad outcome (e.g. death) and an undesirable effect if it is a good outcome (e.g. birth of a healthy baby). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>What is the difference between absolute and relative effects?</b> </p> <p>The effect of an intervention can be described by comparing the risk of the intervention group with the risk of the control group. Such a comparison can be made in different ways. </p> <p>One way to compare two risks is to calculate the difference between the risks. This is the absolute effect. </p> <p>Consider the risk for blindness in a person with diabetes over a five‐year period. If the risk for blindness is found to be 20 in 1000 (2%) in a group of people treated conventionally and 10 in 1000 (1%) in people treated with a new drug, the absolute effect is derived by subtracting the intervention group risk from the control group risk: 2%/1% = 1%. Expressed in this way, it can be said that the new drug reduces the five‐year risk for blindness by 1% (absolute effect is 10 fewer per 1000). </p> <p>Another way to compare risks is to calculate the ratio of the two risks. Given the data above, the relative effect is derived by dividing the two risks, with the intervention risk being divided by the control risk: 1% ÷ 2% = ½ (0.50). Expressed in this way, as the 'relative effect', the five‐year risk for blindness with the new drug is 1/2 the risk with the conventional drug. </p> <p>Here the table presents risks as x per 1000 (or 100, etc.) instead of %, as this tends to be easier to understand. Whenever possible, the table presents the relative effect as the RR. </p> <p>Usually the absolute effect is different for groups that are at high and low risk, whereas the relative effect often is the same. Therefore, when it is relevant, we have reported indicative risks for groups at different levels of risk. Two or three indicative control group risks and the corresponding intervention group risks are presented when there are important differences across different populations. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean difference (MD) is the average difference between the intervention group and the control group across trials. Here a weighted MD is used, which means the results of some of the trials make a greater contribution to the average than others. Trials with more precise estimates for their results (narrower confidence intervals) are given more weight. </p> <p>This way of measuring effect is used when combining or comparing data for continuous outcomes, such as weight, blood pressure, or pain measured on a scale. When different scales are used to measure the same outcome, e.g. different pain scales, a standardised mean difference (SMD) may be provided. This is a weighted mean difference standardised across trials giving the average difference in standard deviations for the measures of that outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confidence interval</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A confidence interval (CI) is a range around an estimate that conveys how precise the estimate is; in this example the result is the estimate of the intervention group risk. The CI is a guide to how sure we can be about the quantity we are interested in (here the true absolute effect). The narrower the range between the two numbers, the more confident we can be about what the true value is; the wider the range, the less sure we can be. The width of the CI reflects the extent to which chance may be responsible for the observed estimate (with a wider interval reflecting more chance). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% confidence interval</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As explained above, the CI indicates the extent to which chance may be responsible for the observed numbers. In the simplest terms, a 95% CI means that we can be 95% confident that the true size of effect is between the lower and upper confidence limit (e.g. 0 and 3 in the blindness drugs example mentioned above). Conversely, there is a 5% chance that the true effect is outside of this range. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant means that a result is unlikely to have occurred by chance. The usual threshold for this judgement is that the results, or more extreme results, would occur by chance with a probability of less than 0.05 if the null hypothesis (no effect) were true. When results are not statistically significant, as in this example, this is stated to alert users to the possibility that the results may have occurred by chance. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants (trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The table provides the total number of participants across trials and the number of trials that provided data for that outcome. This indicates how much evidence there is for the outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty of the evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The certainty of the evidence is a judgement about the extent to which we can be confident that the estimates of effect are correct. These judgements are made using the GRADE system, and are provided for each outcome. The judgements are based on the type of study design (randomised trials versus observational trials), the risk of bias, the consistency of the results across trials, and the precision of the overall estimate across trials. </p> <p>For each outcome, the certainty of the evidence is rated as high, moderate, low, or very low using the following definitions: </p> <p> <ul id="CD011746-list-0018"> <li> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect </p> </li> <li> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> </li> <li> <p><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect </p> </li> <li> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A ‐ indicates that the information is not relevant.</p> </td> </tr> </tbody> </table> </div> <p>These grades are defined as follows.</p> <p> <ul id="CD011746-list-0019"> <li> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011746-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011746-sec-0070"></div> <section id="CD011746-sec-0071"> <h3 class="title">Description of studies</h3> <section id="CD011746-sec-0072"> <h4 class="title">Results of the search</h4> <p>We identified 3161 records from our database searches (<a href="#CD011746-fig-0001">Figure 1</a>). Among the identified 3161 records, the number of duplicates that we found and removed was 620 records. Thus, the final number of records that we scanned was 2541. Based on the titles and abstracts of these records, we excluded 2521 records and further assessed the retrieved full‐text paper publications of the remaining 20 records (<a href="#CD011746-fig-0001">Figure 1</a>). We found seven randomised clinical trials described in seven publications which fulfilled the inclusion criteria of our systematic review (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>; <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>; <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>). Co‐interventions (other than gemcitabine) were equally applied in three trials (<a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>: gemcitabine plus S‐1 versus S‐1 alone; <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>: gemcitabine plus vandetanib versus vandetanib alone; <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>: gemcitabine plus S‐1 versus S‐1 alone), while in the other four trials co‐interventions were unequally applied (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>: gemcitabine plus mitomycin C versus capecitabine plus mitomycin C; <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>: gemcitabine plus oxaliplatin versus 5‐fluorouracil plus folinic acid versus best supportive care; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>: gemcitabine plus cisplatin versus S‐1 plus cisplatin; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>: gemcitabine plus oxaliplatin versus chemoradiotherapy protocol). The trials were set in single countries, conducted in India, Japan, France, Austria, South Korea, China, and Italy. The median age in the seven trials varied between 50 and 60 years and the numbers of included men and women were comparable in most of the trials. All the included trials were parallel‐group trials. </p> <div class="figure" id="CD011746-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011746-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We excluded the remaining 13 publications as they did not fulfil the inclusion criteria of our review (<a href="./references#CD011746-bbs2-0015" title="RadererM , HejnaMH , ValencakJB , KornekGV , WeinländerGS , BareckE , et al. Two consecutive phase II studies of 5‐fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology1999;56(3):177‐80. ">Raderer 1999</a>; <a href="./references#CD011746-bbs2-0017" title="ValleJW , WasanH , JohnsonP , JonesE , DixonL , SwindellR , et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study ‐ the UK ABC‐01 Study. British Journal of Cancer2009;101(4):621‐7. ">Valle 2009</a>; <a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>; <a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>; <a href="./references#CD011746-bbs2-0009" title="LeeJ , ParkSH , ChangHM , KimJS , ChoiHJ , LeeMA , et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary‐tract cancer: a multicentre, open‐label, randomised, phase 3 study. Lancet Oncology2012;13(2):181‐8. ">Lee 2012</a>; <a href="./references#CD011746-bbs2-0016" title="SasakiT , IsayamaH , NakaiY , ItoY , YasudaI , TodaN , et al. A randomized phase II study of gemcitabine and S‐1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology2013;71(4):973–9. ">Sasaki 2013</a>; <a href="./references#CD011746-bbs2-0012" title="MalkaD , CerveraP , FoulonS , TrarbachT , De laFouchardiereC , BoucherE , et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary‐tract cancer (BINGO): a randomised, open‐label, non‐comparative phase 2 trial. Lancet Oncology2014;15(8):819‐28. ">Malka 2014</a>; <a href="./references#CD011746-bbs2-0013" title="MoehlerM , MadererA , SchimanskiC , KanzlerS , DenzerU , KolligsFT , et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double‐blind placebo‐controlled multicentre phase II Aio study with biomarker and serum programme. European Journal of Cancer2014;50(18):3125‐35. ">Moehler 2014</a>; <a href="./references#CD011746-bbs2-0020" title="WanY , HuiH , WangX , LiuH . Random and control study comparing gemcitabine administered in fixed dose rate with a more standard infusion combined with oxaliplatin regimens in advanced biliary tract cancer patients. Chinese Journal of Clinical Oncology2014;41:1098‐102. ">Wan 2014</a>; <a href="./references#CD011746-bbs2-0008" title="ChenJS , HsuC , ChiangNJ , TsaiCS , TsouHH , HuangSF , et al. A KRAS mutation status‐stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of Oncology2015;26(5):943‐9. ">Chen 2015</a>; <a href="./references#CD011746-bbs2-0010" title="LeeJ , HongTH , LeeIS , YouYK , LeeMA . Comparison of the efficacy between gemcitabine‐cisplatin and capecitabine‐cisplatin combination chemotherapy for advanced biliary tract cancer. Cancer Research and Treatment2015;47(2):259‐65. ">Lee 2015</a>; <a href="./references#CD011746-bbs2-0019" title="ValleJW , WasanH , LopesA , BackenAC , PalmerDH , MorrisK , et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC‐03): a randomised phase 2 trial. Lancet Oncology2015;16(8):967‐78. ">Valle 2015</a>; <a href="./references#CD011746-bbs2-0011" title="LeoneF , MarinoD , CeredaS , FilippiR , BelliC , SpadiR , et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti‐BIL study). Cancer2016;122(4):574‐81. ">Leone 2016</a>). We also found three ongoing randomised trials of interest to our review (<a href="./references#CD011746-bbs2-0021" title="NCT01470443 . Study of GEMOX(gemcitabine/oxaliplatin) versus XELOX(xeloda/oxaliplatin) in advanced biliary tract carcinoma [A randomized, multicenter, open‐label, phase 3 study to compare the efficacy and safety of GEMOX(gemcitabine/oxaliplatin) vs XELOX(xeloda/Oxaliplatin) in advanced biliary tract carcinoma]. clinicaltrials.gov/ct2/show/NCT01470443 (first received 11 November 2011). ">NCT01470443</a>; <a href="./references#CD011746-bbs2-0022" title="NCT02591030 . Safety and efficacy of modified folfirinox versus gemcis in bile duct tumours (AMEBICA) [Randomised phase II/III study, assessing the safety and efficacy of modified folfirinox versus gemcis in locally advanced, unresectable and/or metastatic bile duct tumours]. clinicaltrials.gov/ct2/show/NCT02591030 (first received 29 October 2015). ">NCT02591030</a>; <a href="./references#CD011746-bbs2-0023" title="NCT03044587 . Nal‐IRI with 5‐fluorouracil (5‐FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary‐tract cancer (NIFE) [Nal‐IRI with 5‐fluorouracil (5‐FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary‐tract cancer ‐ an open label, non‐comparative, randomized, multicenter phase II Trial]. clinicaltrials.gov/ct2/show/NCT03044587 (first received 7 February 2017). ">NCT03044587</a>). </p> <section id="CD011746-sec-0073"> <h5 class="title">Included studies</h5> </section> </section> <section id="CD011746-sec-0074"> <h4 class="title">Included studies</h4> <p>We included seven studies with a total of 600 participants in this systematic review (<a href="./references#CD011746-sec-0161" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> randomised 173 participants (recruited from October 2008 to September 2012) at 19 centres across Italy. The trial participants were randomised in a 1:1:1 ratio to three treatment groups: a comparator group of vandetanib 300 mg monotherapy (group A), two intervention groups of vandetanib 100 mg plus gemcitabine (group B), and gemcitabine plus placebo (group C). Planned outcomes were progression‐free survival, overall survival, response rate, disease control rate, duration of response, performance status and safety outcomes. For data analysis purposes, both the gemcitabine plus vandetanib group and the gemcitabine plus placebo group were considered as the experimental intervention groups, and outcomes from each of these groups were compared against the vandetanib monotherapy (i.e. non‐gemcitabine‐containing comparator) control group. </p> <p><a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a> randomised 96 participants (enrolled from March 2008 to March 2009); 49 participants were randomised to the experimental intervention (gemcitabine (1000 mg/m<sup>2</sup> IV at 10 mg/m<sup>2</sup>/min on days 1 and 8) and cisplatin (60 mg/m<sup>2</sup> intravenously (IV) on day 1) every three weeks) and 47 participants to the control intervention (S‐1 (40 mg/m<sup>2</sup> orally twice a day on days 1 and 14) plus cisplatin (60 mg/m<sup>2</sup> IV on day 1). Planned outcomes were progression‐free survival, response rate, overall survival, and toxicity. </p> <p><a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> randomised 101 participants (from February 2009 to April 2010) to an experimental intervention of gemcitabine (gemcitabine: 1000 mg/m<sup>2</sup>, day 1 and day 8; S‐1: 60 mg/m<sup>2</sup>, twice daily on days 1 and 14, repeated every three weeks plus S‐1 (a combination of tegafur, gimeracil, and oteracil); and a control intervention of S‐1 (80 mg/m<sup>2</sup>, days 1 to 28, given orally twice daily for four weeks, followed by a two‐week rest, repeated every six weeks). Planned outcomes were progression‐free survival, overall survival, response rate in participants with measurable lesions, the incidences of adverse events, and serious adverse events. </p> <p><a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a> randomised 75 participants to three treatment groups: two control intervention groups of S‐1 monotherapy (orally twice daily for 14 days, followed by a 14‐day rest: group A) and gemcitabine monotherapy (1000 mg/m<sup>2</sup> intravenously over 30 minutes on days 1, 8, and 15: group B), and one experimental intervention group of gemcitabine (in the same dose) plus S‐1: group C. All participants were treated within a four‐week cycle. Planned outcomes were overall survival, progression‐free survival, objective response rate, and safety of chemotherapeutic agents. For data analysis purposes, the (gemcitabine/S‐1) group was considered as the intervention group and we compared outcomes from this group against the S‐1 monotherapy group (i.e. non‐gemcitabine‐containing comparator). We excluded the third group of gemcitabine/placebo from the analysis, following our protocol. </p> <p><a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a> randomised 81 participants (from June 2006 to October 2008) into three groups, including two control intervention groups (group A: best supportive care (27 participants); group B: 5‐fluorouracil and folinic acid (28 participants)), and an experimental intervention group (group C: gemcitabine plus oxaliplatin (26 participants)), for a maximum of six cycles. Planned outcomes included progression‐free survival, response rate, overall survival, and toxicity patterns. For our analysis, we divided the intervention group into two equal halves and compared each half with a different comparator group. </p> <p><a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a> randomised 34 participants (between July 2006 and December 2010) with locally‐advanced biliary tract cancers to an experimental intervention (16 participants in the gemcitabine‐based chemotherapy group) and control intervention (18 participants in the chemoradiotherapy group). Chemoradiotherapy consisted of 5‐fluorouracil infusion and cisplatin, and was given in association with radiotherapy (50 Gy), while gemcitabine‐based chemotherapy consisted of gemcitabine combined with oxaliplatin (GEMOX) for six months. Planned outcomes were overall progression‐free survival, overall survival, toxicity, rate of biliary complications, and duration of hospitalisation. </p> <p><a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a> randomised 51 participants (enrolment dates were not reported in the published paper) to group A (experimental intervention): mitomycin C 8 mg/m<sup>2</sup> on day 1 in combination with gemcitabine 2000 mg/m<sup>2</sup> on days 1 and 15 every four weeks; or group B (control intervention): mitomycin C 8 mg/m<sup>2</sup> on day 1 plus capecitabine 2000 mg/m<sup>2</sup>/day on days 1 and 14, every four weeks. In both groups, chemotherapy was administered for six months, unless progression of disease occurred earlier. Planned outcomes were progression‐free survival, response rate, overall survival, and treatment tolerance. </p> </section> <section id="CD011746-sec-0075"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies, as they did not fulfil our inclusion criteria (<a href="./references#CD011746-sec-0162" title="">Characteristics of excluded studies</a>). In <a href="./references#CD011746-bbs2-0015" title="RadererM , HejnaMH , ValencakJB , KornekGV , WeinländerGS , BareckE , et al. Two consecutive phase II studies of 5‐fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology1999;56(3):177‐80. ">Raderer 1999</a> study, the results of the prospectively‐enrolled participants to the gemcitabine group were retrospectively compared to a patient cohort treated with 5‐fluorouracil, leucovorin (LV) plus mitomycin C. <a href="./references#CD011746-bbs2-0010" title="LeeJ , HongTH , LeeIS , YouYK , LeeMA . Comparison of the efficacy between gemcitabine‐cisplatin and capecitabine‐cisplatin combination chemotherapy for advanced biliary tract cancer. Cancer Research and Treatment2015;47(2):259‐65. ">Lee 2015</a> was a retrospective analysis of clinical data through reviewing medical records to compare the efficacy of gemcitabine‐cisplatin versus capecitabine‐cisplatin combination chemotherapy. In the three UK ABC trials (<a href="./references#CD011746-bbs2-0017" title="ValleJW , WasanH , JohnsonP , JonesE , DixonL , SwindellR , et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study ‐ the UK ABC‐01 Study. British Journal of Cancer2009;101(4):621‐7. ">Valle 2009</a>; <a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>; <a href="./references#CD011746-bbs2-0019" title="ValleJW , WasanH , LopesA , BackenAC , PalmerDH , MorrisK , et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC‐03): a randomised phase 2 trial. Lancet Oncology2015;16(8):967‐78. ">Valle 2015</a>), gemcitabine was used in both groups of each of the three randomised trials. Similarly, the trials of <a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>; <a href="./references#CD011746-bbs2-0009" title="LeeJ , ParkSH , ChangHM , KimJS , ChoiHJ , LeeMA , et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary‐tract cancer: a multicentre, open‐label, randomised, phase 3 study. Lancet Oncology2012;13(2):181‐8. ">Lee 2012</a>; <a href="./references#CD011746-bbs2-0016" title="SasakiT , IsayamaH , NakaiY , ItoY , YasudaI , TodaN , et al. A randomized phase II study of gemcitabine and S‐1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology2013;71(4):973–9. ">Sasaki 2013</a>; <a href="./references#CD011746-bbs2-0012" title="MalkaD , CerveraP , FoulonS , TrarbachT , De laFouchardiereC , BoucherE , et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary‐tract cancer (BINGO): a randomised, open‐label, non‐comparative phase 2 trial. Lancet Oncology2014;15(8):819‐28. ">Malka 2014</a>; <a href="./references#CD011746-bbs2-0013" title="MoehlerM , MadererA , SchimanskiC , KanzlerS , DenzerU , KolligsFT , et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double‐blind placebo‐controlled multicentre phase II Aio study with biomarker and serum programme. European Journal of Cancer2014;50(18):3125‐35. ">Moehler 2014</a>; <a href="./references#CD011746-bbs2-0020" title="WanY , HuiH , WangX , LiuH . Random and control study comparing gemcitabine administered in fixed dose rate with a more standard infusion combined with oxaliplatin regimens in advanced biliary tract cancer patients. Chinese Journal of Clinical Oncology2014;41:1098‐102. ">Wan 2014</a>; <a href="./references#CD011746-bbs2-0008" title="ChenJS , HsuC , ChiangNJ , TsaiCS , TsouHH , HuangSF , et al. A KRAS mutation status‐stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of Oncology2015;26(5):943‐9. ">Chen 2015</a> and <a href="./references#CD011746-bbs2-0011" title="LeoneF , MarinoD , CeredaS , FilippiR , BelliC , SpadiR , et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti‐BIL study). Cancer2016;122(4):574‐81. ">Leone 2016</a> used gemcitabine in both randomised groups of the trial. </p> </section> </section> <section id="CD011746-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical presentation of risk of bias of the included trials, see <a href="#CD011746-fig-0002">Figure 2</a> and <a href="#CD011746-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011746-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD011746-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD011746-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD011746-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD011746-sec-0077"> <h4 class="title">Allocation</h4> <p>Both allocation sequence generation and allocation concealment were clearly reported in four trials (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>; <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>), while it was unclear in three trials (<a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>). </p> </section> <section id="CD011746-sec-0078"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was clearly reported in the <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> trial; unclearly reported in the <a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a> trial; with a high risk of performance bias in <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a> and <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>. Blinding of outcome assessment was clearly reported in the <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> trial; unclearly reported by <a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a> and <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>; with a high risk of detection bias in <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> and <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>. </p> </section> <section id="CD011746-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of attrition bias in all included trials except for <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>, where we rated the risk of attrition bias as high. </p> </section> <section id="CD011746-sec-0080"> <h4 class="title">Selective reporting</h4> <p>There was a low risk of reporting bias in all the included trials except for <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>, where we rated the risk of reporting bias as high, and except for <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> where we rated the risk of reporting bias as unclear. </p> <section id="CD011746-sec-0081"> <h5 class="title">For‐profit bias</h5> <p>There was a high risk of for‐profit bias in <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a> and <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> (because of industry sponsorship), while there was a low risk of for‐profit bias in <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> and <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>, and unclear risk in <a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a> and <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a> trials. </p> </section> </section> <section id="CD011746-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>We found no evidence of other biases in the included trials.</p> <p>Overall, we assessed all of the included trials at high risk of bias in at least one of the above domains; thus, all trials were considered at high overall risk of bias. </p> </section> </section> <section id="CD011746-sec-0083"> <h3 class="title" id="CD011746-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD011746-tbl-0001"><b>Summary of findings for the main comparison</b> Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0002"><b>Summary of findings 2</b> Gemcitabine versus vandetanib for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0003"><b>Summary of findings 3</b> Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0004"><b>Summary of findings 4</b> Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0005"><b>Summary of findings 5</b> Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0006"><b>Summary of findings 6</b> Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0007"><b>Summary of findings 7</b> Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</a>; <a href="./full#CD011746-tbl-0008"><b>Summary of findings 8</b> Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas</a> </p> <section id="CD011746-sec-0084"> <h4 class="title">1. Gemcitabine plus vandetanib versus vandetanib alone</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>). </p> <section id="CD011746-sec-0085"> <h5 class="title">All‐cause mortality</h5> <p>There was no mention of all‐cause mortality in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0086"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0087"> <h5 class="title">Serious adverse events</h5> <p>In <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>, we found no overt differences between the treatment groups in the proportion of participants who experienced serious adverse events (16 participants (27.1%) in the vandetanib monotherapy group and 15 participants (25.9%) in the gemcitabine/vandetanib combination group). Types of serious adverse events reported in this trial included hepatic toxicities, haematological toxicities, and infections. Risk ratio (RR) for the probability of serious adverse events was 0.95 (95% confidence interval (CI) 0.52 to 1.74; P = 0.88; participants = 117; <a href="./references#CD011746-fig-0005" title="">Analysis 1.1</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0088"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0089"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (combination of complete response with partial response) was 5.40 (95% CI 1.25 to 23.29; P = 0.02; participants = 117; <a href="./references#CD011746-fig-0006" title="">Analysis 1.2</a>), favouring the gemcitabine‐based regimen. Overall response rate was not stratified in this trial by tumour site, tumour stage, or performance status. </p> </section> <section id="CD011746-sec-0090"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised in all the included trials according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four. </p> <p>RR for all grades of anaemia (grade 1 ‐ 4) was 7.12 (95% CI 0.90 to 56.08; P = 0.06; participants = 117; <a href="./references#CD011746-fig-0007" title="">Analysis 1.3</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade anaemia (grade 3 ‐ 4) was 3.05 (95% CI 0.13 to 73.39; P = 0.49; participants = 117; <a href="./references#CD011746-fig-0008" title="">Analysis 1.4</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for all grades of neutropenia (grade 1 ‐ 4) was 15.25 (95% CI 0.89 to 261.11; P = 0.06; participants = 117; <a href="./references#CD011746-fig-0009" title="">Analysis 1.5</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade neutropenia (grade 3 ‐ 4) was 9.15 (95% CI 0.50 to 166.27; P = 0.13; participants = 117; <a href="./references#CD011746-fig-0010" title="">Analysis 1.6</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> </section> <section id="CD011746-sec-0091"> <h4 class="title">2. Gemcitabine versus vandetanib</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>). </p> <section id="CD011746-sec-0092"> <h5 class="title">All‐cause mortality</h5> <p>There was no mention of all‐cause mortality in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0093"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0094"> <h5 class="title">Serious adverse events</h5> <p>In <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>, we found no overt differences between the treatment groups in the proportion of participants who experienced serious adverse events (12 participants in the gemcitabine monotherapy group and 16 participants in the vandetanib monotherapy group). The RR for the probability of serious adverse events was 0.79 (95% CI 0.41 to 1.52; P = 0.48; participants = 115; <a href="./references#CD011746-fig-0011" title="">Analysis 2.1</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0095"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0096"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (combination of complete response with partial response) was 3.77 (95% CI 0.82 to 17.33; P = 0.09; participants = 108; <a href="./references#CD011746-fig-0012" title="">Analysis 2.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. Overall response rate was not stratified in this trial by tumour site, tumour stage, or performance status. </p> </section> <section id="CD011746-sec-0097"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four. </p> <p>RR for all grades of anaemia (grade 1 ‐ 4) was 7.38 (95% CI 0.94 to 58.05; P = 0.06; participants = 115; <a href="./references#CD011746-fig-0013" title="">Analysis 2.3</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade anaemia (grade 3 ‐ 4) was 3.16 (95% CI 0.13 to 75.94; P = 0.48; participants = 115; <a href="./references#CD011746-fig-0014" title="">Analysis 2.4</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for all grades of neutropenia (grade 1 ‐ 4) was 22.11 (95% CI 1.33 to 368.56; P = 0.03; participants = 115; <a href="./references#CD011746-fig-0015" title="">Analysis 2.5</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade neutropenia (grade 3 ‐ 4) was 11.58 (95% CI 0.66 to 204.68; P = 0.09; participants = 115; <a href="./references#CD011746-fig-0016" title="">Analysis 2.6</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> </section> <section id="CD011746-sec-0098"> <h4 class="title">3. Gemcitabine plus cisplatin versus S‐1 plus cisplatin</h4> <p>One trial contributed data related to this comparison (<a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>). </p> <section id="CD011746-sec-0099"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 0.76 (95% CI 0.58 to 0.98; P = 0.04; participants = 96; <a href="./references#CD011746-fig-0017" title="">Analysis 3.1</a>), favouring gemcitabine‐based chemotherapy. All‐cause mortality was not stratified by tumour site, tumour stage, or performance status. In <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>, all‐cause mortality was reported in the text at eight months, and we extracted the one‐year mortality from the survival curve in order for the result to be consistent with all‐cause mortality from other comparisons. </p> </section> <section id="CD011746-sec-0100"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0101"> <h5 class="title">Serious adverse events</h5> <p>There was no mention of serious adverse events in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0102"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0103"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (complete response and partial response) was 0.82 (95% CI 0.37 to 1.82; P = 0.63; participants = 88; <a href="./references#CD011746-fig-0018" title="">Analysis 3.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. Overall response rate was not stratified in this trial by tumour site, tumour stage, or performance status. </p> </section> <section id="CD011746-sec-0104"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised in all the included trials according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four.<br/> <br/> RR for all grades of anaemia (grade 1 ‐ 4) was 11.27 (95% CI 4.41 to 28.83; P &lt; 0.001; participants = 96; <a href="./references#CD011746-fig-0019" title="">Analysis 3.3</a>), favouring non‐gemcitabine‐based regimens.<br/> RR for high‐grade anaemia (grade 3 ‐ 4) was 10.55 (95% CI 1.42 to 78.56; P = 0.02; participants = 96; <a href="./references#CD011746-fig-0020" title="">Analysis 3.4</a>), favouring non‐gemcitabine regimens.<br/> RR for all grades of thrombocytopenia (grade 1 ‐ 4) was 6.71 (95% CI 2.55 to 17.68 ; P &lt; 0.001; participants = 96; <a href="./references#CD011746-fig-0021" title="">Analysis 3.5</a>), favouring non‐gemcitabine regimens.<br/> RR for high‐grade thrombocytopenia (grade 3 ‐ 4) was 5.28 (95% CI 1.23 to 22.55 ; P = 0.02; participants = 96; <a href="./references#CD011746-fig-0022" title="">Analysis 3.6</a>), favouring non‐gemcitabine regimens.<br/> RR for all grades of neutropenia (grade 1 ‐ 4) was 1.28 (95% CI 0.95 to 1.72 ; P = 0.11; participants = 96; <a href="./references#CD011746-fig-0023" title="">Analysis 3.7</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade neutropenia (grade 3 ‐ 4) was 1.64, 95% CI 0.97 to 2.78 ; P = 0.06; <a href="./references#CD011746-fig-0024" title="">Analysis 3.8</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for febrile neutropenia was 4.80 (95% CI 0.24 to 97.42 ; P = 0.31; participants = 96; <a href="./references#CD011746-fig-0025" title="">Analysis 3.9</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> </section> <section id="CD011746-sec-0105"> <h4 class="title">4. Gemcitabine plus S‐1 versus S‐1</h4> <p>Two trials included data related to this comparison (<a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>). </p> <section id="CD011746-sec-0106"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 0.61 (95% CI 0.33 to 1.13; P = 0.12; participants = 151; trials = 2; I<sup>2</sup> = 76% (significant heterogeneity); <a href="./references#CD011746-fig-0026" title="">Analysis 4.1</a>), favouring neither gemcitabine nor non‐gemcitabine‐based chemotherapy. All‐cause mortality was not stratified in this trial by tumour site, tumour stage, or performance status. In both trials, all‐cause mortality was reported at one year. In order to detect or reject a risk reduction of 20%, the diversity‐adjusted required information size was n = 2655 trial participants, based upon a proportion of death of 70% of participants in S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. Using the random‐effects model Trial Sequential Analysis, the resulting cumulative test statistic (Z‐score) did not cross the adjusted threshold for statistical significance (<a href="#CD011746-fig-0004">Figure 4</a>). The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40. </p> <div class="figure" id="CD011746-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40." data-id="CD011746-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40. </p> </div> </div> </div> </section> <section id="CD011746-sec-0107"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0108"> <h5 class="title">Serious adverse events</h5> <p>This was covered only by the <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> trial, in which two serious adverse events were reported in each group (gemcitabine/S‐1 group and S‐1 monotherapy group). Types of serious adverse events in this study included pneumonia, myocardial infarction, and hyponatraemia. The RR for the probability of serious adverse events was: 1.05 (95% CI 0.15 to 7.10; P = 0.96; participants = 90; <a href="./references#CD011746-fig-0027" title="">Analysis 4.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0109"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0110"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (complete response and partial response) was 2.46 (95% CI 1.27 to 4.75; P = 0.007; I<sup>2</sup> = 0%; participants = 140; <a href="./references#CD011746-fig-0028" title="">Analysis 4.3</a>), favouring the gemcitabine‐based regimen. The overall response rate was stratified according to tumour site only in the <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> trial, in which the participants with gall bladder carcinomas achieved an overall response rate of 12.5% (2 ⁄ 16) in the gemcitabine plus S‐1 group and 16.7% (3 ⁄ 18) in the S‐1 alone group. The overall response rate for participants with non‐gall bladder carcinomas was 50% (14 ⁄ 28) in the gemcitabine plus S‐1 group and 17.9% (5 ⁄ 28) in the S‐1 alone group. </p> </section> <section id="CD011746-sec-0111"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised in all included trials according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four.<br/> RR for all grades of anaemia (grade 1 ‐ 4) was 1.26 (95% CI 1.00 to 1.59; P = 0.05; participants = 151; I<sup>2</sup> = 0%; <a href="./references#CD011746-fig-0029" title="">Analysis 4.4</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade anaemia (grade 3 ‐ 4) was 2.94 (95% CI 0.62 to 13.89; P = 0.17; participants = 101; <a href="./references#CD011746-fig-0030" title="">Analysis 4.5</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for all grades of thrombocytopenia (grade 1 ‐ 4) was 2.45 (95% CI 1.39 to 4.32 ; P = 0.002; I<sup>2</sup> = 0%; participants = 151; <a href="./references#CD011746-fig-0031" title="">Analysis 4.6</a>), favouring non‐gemcitabine regimens.<br/> RR for high‐grade thrombocytopenia (grade 3 ‐ 4) was 2.94 (95% CI 0.62 to 13.89; P = 0.17; participants = 101; <a href="./references#CD011746-fig-0032" title="">Analysis 4.7</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for all grades of neutropenia (grade 1 ‐ 4) was 3.30 (95% CI 1.04 to 10.50 ; P = 0.04; I<sup>2</sup> = 66%; participants = 151; <a href="./references#CD011746-fig-0033" title="">Analysis 4.8</a>), favouring non‐gemcitabine regimens.<br/> RR for high‐grade neutropenia (grade 3 ‐ 4) was 15.20 (95% CI 3.84 to 60.14; P &lt; 0.001; <a href="./references#CD011746-fig-0034" title="">Analysis 4.9</a>), favouring non‐gemcitabine regimens.<br/> RR for febrile neutropenia was 2.97 (95% CI 0.32 to 27.87; P = 0.34; I<sup>2</sup> = 0%; participants = 151; <a href="./references#CD011746-fig-0035" title="">Analysis 4.10</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> </section> <section id="CD011746-sec-0112"> <h4 class="title">5. Gemcitabine plus oxaliplatin versus best supportive care</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>). </p> <section id="CD011746-sec-0113"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 0.78 (95% CI 0.53 to 1.15; P = 0.20; participants = 40; <a href="./references#CD011746-fig-0036" title="">Analysis 5.1</a>), favouring neither gemcitabine nor non‐gemcitabine‐based chemotherapy. All‐cause mortality was not stratified in this trial by tumour site, tumour stage, or performance status. The trial reports all‐cause mortality at one year. </p> </section> <section id="CD011746-sec-0114"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0115"> <h5 class="title">Serious adverse events</h5> <p>There was no mention of serious adverse events in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0116"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0117"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (complete response and partial response) was 34.00 (95% CI 2.11 to 547.54; P = 0.01; participants = 40; <a href="./references#CD011746-fig-0037" title="">Analysis 5.2</a>), favouring the gemcitabine‐based regimen. </p> </section> <section id="CD011746-sec-0118"> <h5 class="title">Non‐serious adverse events</h5> <p>There was no mention of non‐serious adverse events in any of the groups of this comparison.</p> </section> </section> <section id="CD011746-sec-0119"> <h4 class="title">6. Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus folinic acid</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>). </p> <section id="CD011746-sec-0120"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 0.81 (95% CI 0.55 to 1.20 ; P = 0.29; participants = 41; <a href="./references#CD011746-fig-0038" title="">Analysis 6.1</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. All‐cause mortality was not stratified in this trial by tumour site, tumour stage, or performance status. The trial reports all‐cause mortality at one year. </p> </section> <section id="CD011746-sec-0121"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0122"> <h5 class="title">Serious adverse events</h5> <p>There was no mention of serious adverse events in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0123"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0124"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in accordance with the response evaluation in solid tumours criteria in this comparison. The RR for overall response rate (complete response and partial response) was 2.15 (95% CI 0.64 to 7.29 ; P = 0.22; participants = 41; <a href="./references#CD011746-fig-0039" title="">Analysis 6.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0125"> <h5 class="title">Non‐serious adverse events</h5> <p>There was no mention of non‐serious adverse events in any of the groups of this comparison.</p> <p>Following our protocol, we have also evaluated the harmful effects from <a href="./references#CD011746-bbs2-0010" title="LeeJ , HongTH , LeeIS , YouYK , LeeMA . Comparison of the efficacy between gemcitabine‐cisplatin and capecitabine‐cisplatin combination chemotherapy for advanced biliary tract cancer. Cancer Research and Treatment2015;47(2):259‐65. ">Lee 2015</a>, which is a retrospective study comparing gemcitabine plus cisplatin to capecitabine plus cisplatin. There were no cases of chemotherapy‐related death or febrile neutropenia reported in this study. The most common haematologic grade 3 ‐ 4 toxicity was neutropenia in both the gemcitabine and non‐gemcitabine groups (15% and 14.4%, respectively). We have also evaluated the harmful effects from <a href="./references#CD011746-bbs2-0015" title="RadererM , HejnaMH , ValencakJB , KornekGV , WeinländerGS , BareckE , et al. Two consecutive phase II studies of 5‐fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology1999;56(3):177‐80. ">Raderer 1999</a>, which is an observational non‐randomised study evaluating 5‐fluorouracil plus mitomycin C (cohort A) or gemcitabine monotherapy (cohort B). Haematologic adverse effects attributable to treatment were modest with both treatment regimens. Grade IV granulocytopenia was seen in 5% of the participants, severe thrombocytopenia occurred in 15% of the participants, and grade III anaemia was seen in 10% of 19 evaluable participants in cohort A. Among the 17 participants of cohort B who were considered evaluable for toxicity, thrombocytopenia was the most commonly‐observed haematologic side effect, with 12% of participants having grade III and 6% with grade IV thrombocytopenia. Only 6% had leukocytopenia grade II, and 6% had anaemia grade I. </p> </section> </section> <section id="CD011746-sec-0126"> <h4 class="title">7. Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>). </p> <section id="CD011746-sec-0127"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 0.56 (95% CI 0.21 to 1.52; P = 0.26; participants = 34; <a href="./references#CD011746-fig-0040" title="">Analysis 7.1</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> All‐cause mortality was not stratified in this trial by tumour site, tumour stage, or performance status. The trial reports all‐cause mortality at one year. </p> </section> <section id="CD011746-sec-0128"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0129"> <h5 class="title">Serious adverse events</h5> <p>In <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>, eight participants suffered serious adverse events in the chemotherapy group versus six participants in the chemoradiotherapy group. The cause of serious adverse events was upper gastrointestinal bleeding in one case, with no mention of the details of hospitalisation of the other 13 participants. The RR for the probability of serious adverse events was 1.50 (95% CI 0.66 to 3.39; P = 0.33; participants = 34; <a href="./references#CD011746-fig-0041" title="">Analysis 7.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0130"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0131"> <h5 class="title">Tumour response assessments</h5> <p>There was no mention of tumour response in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0132"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised in all the included trials according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four.<br/> RR for high‐grade neutropenia (grade 3 ‐ 4) was 10.06 (95% CI 0.58 to 173.47; P = 0.11; participants = 34; <a href="./references#CD011746-fig-0042" title="">Analysis 7.3</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> </section> <section id="CD011746-sec-0133"> <h4 class="title">8. Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C</h4> <p>One trial included data related to this comparison (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>). </p> <section id="CD011746-sec-0134"> <h5 class="title">All‐cause mortality</h5> <p>The RR for all‐cause mortality at one year was 1.14 (95% CI 0.89 to 1.48 ; P = 0.30; participants = 51; <a href="./references#CD011746-fig-0043" title="">Analysis 8.1</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. All‐cause mortality was not stratified in this trial by tumour site, tumour stage, or performance status. The trial reports all‐cause mortality at one year. </p> </section> <section id="CD011746-sec-0135"> <h5 class="title">Health‐related quality of life</h5> <p>There was no mention of health‐related quality of life in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0136"> <h5 class="title">Serious adverse events</h5> <p>There was no mention of serious adverse events in any of the groups of this comparison.</p> </section> <section id="CD011746-sec-0137"> <h5 class="title">Time to progression of the tumour (reported as median time to progression)</h5> <p>There was no mention of time to progression of the tumour in any of the groups of this comparison. </p> </section> <section id="CD011746-sec-0138"> <h5 class="title">Tumour response assessments</h5> <p>Tumour response was evaluated in this study in accordance with the World Health Organization criteria. The RR for overall response rate (complete response and partial response) was 0.65 (95% CI 0.25 to 1.72; P = 0.39; participants = 51; <a href="./references#CD011746-fig-0044" title="">Analysis 8.2</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. Overall response rate was not stratified in this trial by tumour site, tumour stage, or performance status. </p> </section> <section id="CD011746-sec-0139"> <h5 class="title">Non‐serious adverse events</h5> <p>Non‐serious adverse events were categorised in all the included trials according to the National Cancer Institute common terminology criteria (<a href="./references#CD011746-bbs2-0075" title="National Cancer Instiute. Common Terminology Criteria for Adverse Events (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 1 June 2016). ">NCI‐CTC 2016</a>), and we ranked them accordingly into grades one to four.<br/> RR for all grades of thrombocytopenia (grade 1 ‐ 4) was 0.56 (95% CI 0.29 to 1.06; P = 0.07; participants = 47; <a href="./references#CD011746-fig-0045" title="">Analysis 8.3</a>), favouring neither gemcitabine nor non‐gemcitabine regimens.<br/> RR for high‐grade thrombocytopenia (grade 3 ‐ 4) was 0.78 (95% CI 0.20 to 3.12; P = 0.73; participants = 47; <a href="./references#CD011746-fig-0046" title="">Analysis 8.4</a>), favouring neither gemcitabine nor non‐gemcitabine regimens. </p> </section> <section id="CD011746-sec-0140"> <h5 class="title">Summary of findings</h5> <p><a href="./full#CD011746-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011746-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011746-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011746-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD011746-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011746-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD011746-tbl-0007">summary of findings Table 7</a>; and <a href="./full#CD011746-tbl-0008">summary of findings Table 8</a> present our findings on the outcomes: all‐cause mortality, serious adverse events, health‐related quality of life, time to progression of the tumour, and non‐serious adverse events. We downgraded the quality of the evidence by three levels because of within‐study risk of bias due to high risk of bias; publication bias as it could not be assessed; and because of imprecision due to the small number of trials (only one trial or two trials contributing data). The certainty of the evidence of all the presented outcomes is therefore graded as very low. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011746-sec-0141" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011746-sec-0141">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011746-sec-0204">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011746-sec-0141"></div> <section id="CD011746-sec-0142"> <h3 class="title" id="CD011746-sec-0142">Summary of main results</h3> <p>Based on the included trials, gemcitabine plus cisplatin combination may be associated with lower all‐cause mortality compared with S‐1 plus cisplatin combination. Gemcitabine plus vandetanib combination may be associated with higher response rates compared with vandetanib alone. Gemcitabine plus S‐1 combination may be associated with higher response rates compared with S‐1 alone, and gemcitabine plus oxaliplatin may be associated with higher response rates compared with best supportive care. On the other hand, gemcitabine plus cisplatin combination may be associated with a higher risk of all grades and high‐grade anaemia and thrombocytopenia. Similarly, gemcitabine plus S‐1 combination may be associated with a higher risk of all grades of thrombocytopenia, all grades of neutropenia, and high‐grade neutropenia. However, it has to be noted that the included trials were highly heterogeneous in their design, mixing single‐agent chemo‐ or targeted therapy, radiochemotherapy, and supportive care<i>.</i> Thus, taking into consideration the overall low quality of data, we cannot draw definite conclusions. We note also that there were no properly‐performed placebo‐controlled studies in this review. This might have affected the assessment of intervention effects for all outcomes, with the possible exception of mortality. </p> <p>We await the results of three ongoing randomised trials to provide data for this intervention with or without additional treatments for advanced biliary tract carcinoma (<a href="./references#CD011746-bbs2-0022" title="NCT02591030 . Safety and efficacy of modified folfirinox versus gemcis in bile duct tumours (AMEBICA) [Randomised phase II/III study, assessing the safety and efficacy of modified folfirinox versus gemcis in locally advanced, unresectable and/or metastatic bile duct tumours]. clinicaltrials.gov/ct2/show/NCT02591030 (first received 29 October 2015). ">NCT02591030</a>; <a href="./references#CD011746-bbs2-0021" title="NCT01470443 . Study of GEMOX(gemcitabine/oxaliplatin) versus XELOX(xeloda/oxaliplatin) in advanced biliary tract carcinoma [A randomized, multicenter, open‐label, phase 3 study to compare the efficacy and safety of GEMOX(gemcitabine/oxaliplatin) vs XELOX(xeloda/Oxaliplatin) in advanced biliary tract carcinoma]. clinicaltrials.gov/ct2/show/NCT01470443 (first received 11 November 2011). ">NCT01470443</a>; <a href="./references#CD011746-bbs2-0023" title="NCT03044587 . Nal‐IRI with 5‐fluorouracil (5‐FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary‐tract cancer (NIFE) [Nal‐IRI with 5‐fluorouracil (5‐FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary‐tract cancer ‐ an open label, non‐comparative, randomized, multicenter phase II Trial]. clinicaltrials.gov/ct2/show/NCT03044587 (first received 7 February 2017). ">NCT03044587</a>). </p> </section> <section id="CD011746-sec-0143"> <h3 class="title" id="CD011746-sec-0143">Overall completeness and applicability of evidence</h3> <p>The search strategy for randomised clinical trials was very wide, and additionally, by searching the reference lists of the included trials and by checking recent review articles, we made sure that we covered all relevant trials. However, we note that not all of the included trials provided data on all the primary outcomes of interest in this review; moreover, the control regimens are quite variable, which limits the applicability of the evidence. We have not searched the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), or the World Health Organiztion (WHO) clinical registry, and we did not contact pharmaceutical companies for unpublished trials. By focusing mainly on randomised clinical trials and not searching for observational studies reporting adverse events, we are well aware that we bias the review towards focusing more on potential benefits than on potential harms. </p> </section> <section id="CD011746-sec-0144"> <h3 class="title" id="CD011746-sec-0144">Quality of the evidence</h3> <p>The body of collected evidence does not allow a robust conclusion regarding the objectives of the review. We assessed the overall quality of the evidence as being of very low certainty, using the GRADE approach (<a href="./references#CD011746-bbs2-0043" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group 2004‐2007, 2008. ">GRADEpro 2008</a>; <a href="./references#CD011746-bbs2-0026" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines 3: rating the quality of evidence ‐ introduction. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>). This is because of the high risk of bias, small number of trials (imprecision), as well as marked heterogeneity (inconsistency). Details of the risk of bias assessment of included trials were as follows: there was a low risk of reporting bias in all trials except for <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>, and a low risk of attrition bias in all the included trials except for <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>. There was a low risk of performance bias in <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>; unclear risk in <a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a> trial; and a high risk in <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a> and <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>. There was a low risk of detection bias in <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a> trial; unclear risk in <a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; and <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a> trials; and a high risk of detection bias in <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a> and <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a> trials. Detection bias (including allocation sequence generation and allocation concealment) was clearly reported by four trials (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0006" title="SantoroA , GebbiaV , PressianiT , TestaA , PersoneniN , Arrivas BajardiE , et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of Oncology2015;26:542‐7. ">Santoro 2015</a>; <a href="./references#CD011746-bbs2-0003" title="LiH , ZhangZ , ZhouZ , GuanJ , TongD , ZhouG . Combined gemcitabine and S‐1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open‐label clinical trial. Oncotarget2016;7(18):26888‐97. ">Li 2016</a>); while it was unclearly reported by three trials (<a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0005" title="PhelipJ‐M , VendrelyV , RostainF , SubtilF , JouveJ‐L , GasmiM , et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European Journal of Cancer2014;50(17):2975‐82. ">Phelip 2014</a>). </p> </section> <section id="CD011746-sec-0145"> <h3 class="title" id="CD011746-sec-0145">Potential biases in the review process</h3> <p>Publication bias might be an issue here; however, due to the fact that there were only one or two trials for each comparison, we were not able to assess this formally. </p> </section> <section id="CD011746-sec-0146"> <h3 class="title" id="CD011746-sec-0146">Agreements and disagreements with other studies or reviews</h3> <p>A meta‐analysis of individual patient data combining the UK ABC‐02 study (<a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>) and the Japanese BT22 study (<a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>) has been published (<a href="./references#CD011746-bbs2-0096" title="ValleJW , FuruseJ , JitlalM , BeareS , MizunoN , WasanH , et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta‐analysis of two randomised trials. Annals of Oncology2014;25(2):391‐8. ">Valle 2014</a>). However, the main research question of this meta‐analysis was whether or not gemcitabine plus cisplatin combination is better than gemcitabine monotherapy. </p> <p>Another meta‐analysis has evaluated the efficacy and safety of gemcitabine‐based chemotherapies in biliary tract cancer (<a href="./references#CD011746-bbs2-0066" title="LiuH , ZhangQ‐D , LiZ‐H , ZhangQ‐Q , LuL‐G . Efficacy and safety of gemcitabine‐based chemotherapies in biliary tract cancer: a meta‐analysis. World Journal of Gastroenterology2014;20(47):18001‐12. ">Liu 2014</a>), and included seven randomised trials (<a href="./references#CD011746-bbs2-0002" title="KornekGV , SchuellB , LaengleF , GruenbergerT , PenzM , KarallK , et al. Mitomycin C in combination with capecitabine or biweekly high‐dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology2004;15(3):478‐83. ">Kornek 2004</a>; <a href="./references#CD011746-bbs2-0014" title="OkusakaT , NakachiK , FukutomiA , MizunoN , OhkawaS , FunakoshiA , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer2010;103(4):469‐74. ">Okusaka 2010</a>; <a href="./references#CD011746-bbs2-0007" title="SharmaA , DwaryAD , MohantiBK , DeoSV , PalS , SreenivasV , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical Oncology2010;28(30):4581‐6. ">Sharma 2010</a>; <a href="./references#CD011746-bbs2-0018" title="ValleJ , WasanH , PalmarD , CunninghamD , AnthoneyA , MaraveyasA , et al. Cisplatin plus gemcitabine versus cisplatin for biliary tract cancer. New England Journal of Medicine2010;362(14):1273‐8. ">Valle 2010</a>; <a href="./references#CD011746-bbs2-0001" title="KangMJ , LeeJL , KimTW , LeeSS , AhnS , Park doH , et al. Randomized phase II trial of S‐1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncologica2012;51:860‐6. ">Kang 2012</a>; <a href="./references#CD011746-bbs2-0004" title="MorizaneC , OkusakaT , MizusawaJ , TakashimaA , UenoM , IkedaM , et al. Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science2013;104(9):1211‐6. ">Morizane 2013</a>; <a href="./references#CD011746-bbs2-0016" title="SasakiT , IsayamaH , NakaiY , ItoY , YasudaI , TodaN , et al. A randomized phase II study of gemcitabine and S‐1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology2013;71(4):973–9. ">Sasaki 2013</a>); the conclusions indicated that gemcitabine‐based combination chemotherapy is a potential first‐line treatment for advanced biliary tract cancer, based on improved survival, albeit with additional toxicity. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011746-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011746-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD011746-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD011746-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40." data-id="CD011746-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis comparing gemcitabine plus S‐1 versus S‐1 alone on the outcome 'all‐cause mortality'. The diversity‐adjusted required information size (DARIS) of n = 2655 trial participants was calculated based upon a proportion of mortality of 70% of the trial participants in the S‐1 group, a relative risk reduction of 20% in the gemcitabine + S‐1 group, an alpha (type I error) of 2.5%, a beta (type II error) of 10%, and a diversity of 78%. The blue curve presents the cumulative meta‐analysis Z‐score, and the inward‐sloping dotted red curves present the adjusted threshold for statistical significance according to the two‐sided trial sequential monitoring boundaries. The Trial Sequential Analysis‐adjusted CI was 0.27 to 1.40. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 1 Serious adverse events." data-id="CD011746-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 1 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 2 Overall response rate." data-id="CD011746-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 2 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 3 Grade 1 ‐ 4 anaemia." data-id="CD011746-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 3 Grade 1 ‐ 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 4 Grade 3 ‐ 4 anaemia." data-id="CD011746-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 4 Grade 3 ‐ 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 5 Grade 1 ‐ 4 neutropenia." data-id="CD011746-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 5 Grade 1 ‐ 4 neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 6 Grade 3 ‐ 4 neutropenia." data-id="CD011746-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Gemcitabine plus vandetanib versus vandetanib alone, Outcome 6 Grade 3 ‐ 4 neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 1 Serious adverse events." data-id="CD011746-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 2 Overall response rate." data-id="CD011746-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 2 Overall response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 3 Grade 1 ‐ 4 anaemia." data-id="CD011746-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 3 Grade 1 ‐ 4 anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 4 Grade 3 ‐ 4 anaemia." data-id="CD011746-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 4 Grade 3 ‐ 4 anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 5 Grade 1 ‐ 4 neutropenia." data-id="CD011746-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 5 Grade 1 ‐ 4 neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Gemcitabine versus vandetanib, Outcome 6 Grade 3 ‐ 4 neutropenia." data-id="CD011746-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Gemcitabine versus vandetanib, Outcome 6 Grade 3 ‐ 4 neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 2 Overall response rate." data-id="CD011746-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 2 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 3 Grade 1 ‐ 4 anaemia." data-id="CD011746-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 3 Grade 1 ‐ 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 4 Grade 3 ‐ 4 anaemia." data-id="CD011746-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 4 Grade 3 ‐ 4 anaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 5 Grade 1 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 5 Grade 1 ‐ 4 thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 6 Grade 3 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 6 Grade 3 ‐ 4 thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 7 Grade 1 ‐ 4 neutropenia." data-id="CD011746-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 7 Grade 1 ‐ 4 neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 8 Grade 3 ‐ 4 neutropenia." data-id="CD011746-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 8 Grade 3 ‐ 4 neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 9 Febrile neutropenia." data-id="CD011746-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Gemcitabine plus cisplatin versus S‐1 plus cisplatin, Outcome 9 Febrile neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 2 Serious adverse events." data-id="CD011746-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 3 Overall response rate." data-id="CD011746-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 3 Overall response rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 4 Grade 1 ‐ 4 anaemia." data-id="CD011746-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 4 Grade 1 ‐ 4 anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 5 Grade 3 ‐ 4 anaemia." data-id="CD011746-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 5 Grade 3 ‐ 4 anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 6 Grade 1 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 6 Grade 1 ‐ 4 thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 7 Grade 3 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 7 Grade 3 ‐ 4 thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 8 Grade 1 ‐ 4 neutropenia." data-id="CD011746-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 8 Grade 1 ‐ 4 neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 9 Grade 3 ‐ 4 neutropenia." data-id="CD011746-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 9 Grade 3 ‐ 4 neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 10 Febrile neutropenia." data-id="CD011746-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Gemcitabine plus S‐1 versus S‐1, Outcome 10 Febrile neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 2 Overall response rate." data-id="CD011746-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Gemcitabine plus oxaliplatin versus best supportive care, Outcome 2 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 2 Overall response rate." data-id="CD011746-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid, Outcome 2 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 2 Serious adverse events." data-id="CD011746-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 3 Grade 3 ‐ 4 neutropenia." data-id="CD011746-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy, Outcome 3 Grade 3 ‐ 4 neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 1 All‐cause mortality at one year." data-id="CD011746-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 1 All‐cause mortality at one year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 2 Overall response rate." data-id="CD011746-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 2 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 3 Grade 1 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 3 Grade 1 ‐ 4 thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011746-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/urn:x-wiley:14651858:media:CD011746:CD011746-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_t/tCD011746-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 4 Grade 3 ‐ 4 thrombocytopenia." data-id="CD011746-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C, Outcome 4 Grade 3 ‐ 4 thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/media/CDSR/CD011746/image_n/nCD011746-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus vandetanib<br/> <b>Comparison:</b> vandetanib </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vandetanib</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus vandetanib</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.52 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000<br/> (141 to 472) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.40<br/> (1.25 to 23.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>113<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/> (45 to 832) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.12<br/> (0.90 to 56.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000<br/> (15 to 951) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gemcitabine plus vandetanib compared with vandetanib for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gemcitabine versus vandetanib for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gemcitabine compared with vandetanib for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals </p> <p><b>Intervention:</b> gemcitabine </p> <p><b>Comparison:</b> vandetanib </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vandetanib</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000<br/> (111 to 412) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (0.41 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helath‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/> (29 to 619) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.77 (0.82 to 17.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>125 per 1000</p> <p>(16 to 984)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.38 (0.94 to 58.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gemcitabine versus vandetanib for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus cisplatin<br/> <b>Comparison:</b> S‐1 plus cisplatin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with S‐1 plus cisplatin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus cisplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76<br/> (0.58 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>614 per 1000<br/> (469 to 792) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.37 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>88<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/> (88 to 433) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.27<br/> (4.41 to 28.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>959 per 1000<br/> (375 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gemcitabine plus cisplatin compared with S‐1 plus cisplatin for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus S‐1<br/> <b>Comparison:</b> S‐1 </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with S‐1</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus S‐1</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.33 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>431 per 1000<br/> (233 to 799) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.15 to 7.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/> (7 to 309) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.46<br/> (1.27 to 4.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not supported by Trial Sequential Analysis</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>346 per 1000<br/> (179 to 669) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 anaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/> (1.00 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000<br/> (480 to 763) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (two trials) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Gemcitabine plus S‐1 compared with S‐1 for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> best supportive care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with best supportive care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.53 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/> (471 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 34.00<br/> (2.11 to 547.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with best supportive care for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus oxaliplatin compared with fluorouracil plus folinic acid for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> fluorouracil plus folinic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fluorouracil plus folinic acid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.55 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>857 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>694 per 1000<br/> (471 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Helath‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.15<br/> (0.64 to 7.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000<br/> (91 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus folinic acid for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus oxaliplatin compared with fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus oxaliplatin<br/> <b>Comparison:</b> fluorouracil plus cisplatin plus radiotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fluorouracil and cisplatin plus radiotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus oxaliplatin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.21 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<br/> (93 to 676) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.66 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/> (220 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Gemcitabine plus oxaliplatin compared with 5‐fluorouracil plus cisplatin plus radiotherapy for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011746-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gemcitabine plus mitomycin C compared with mitomycin C plus capecitabine for advanced biliary tract carcinomas</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced biliary tract carcinomas<br/> <b>Setting:</b> specialist hospitals<br/> <b>Intervention:</b> gemcitabine plus mitomycin C<br/> <b>Comparison:</b> capecitabine plus mitomycin C </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with capecitabine plus mitomycin C</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gemcitabine plus mitomycin C</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 1 year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.89 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>769 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>877 per 1000<br/> (685 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/> (0.25 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000<br/> (77 to 529) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to progression of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Grade 1 ‐ 4 thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.29 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000<br/> (181 to 663) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT</b>: randomised clinical trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three levels (‐3) because of i) within‐study risk of bias due to high risk of bias; ii) publication bias could not be assessed; iii) imprecision due to small number of trials (one trial) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Gemcitabine plus mitomycin C compared with capecitabine plus mitomycin C for advanced biliary tract carcinomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011746-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Explanations for Cochrane 'Summary of findings' tables</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Examples from table</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The tables provide the findings for the most important outcomes for someone making a decision. These include potential benefits and harms, whether the included trials provide data for these outcomes or not. Additional findings may be reported elsewhere in the review. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed control group risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assumed control group risks can be based either on the control group risks reported in the included trials or on epidemiological data from elsewhere. When only one control group risk is provided, it is normally the median control group risk across the trials that provided data for that outcome. </p> <p>Risk is the probability of an outcome occurring. The control group risk is the risk of an outcome occurring in the comparison group (without the intervention). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corresponding intervention group risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk is the probability of an outcome occurring. The intervention group risk is the risk of an outcome occurring in the group receiving the intervention. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Relative effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect or RR (risk ratio)</b> </p> <p>Relative effects are ratios. Here the relative effect is expressed as a risk ratio.</p> <p>Risk is the probability of an outcome occurring. An RR is the ratio between the risk in the intervention group and the risk in the control group. If the risk in the control group is 10% (100 per 1000) and the risk in the intervention group is 1% (10 per 1000), the RR is 10/100 or 0.10. </p> <p>If the RR is exactly 1.0, this means that there is no difference between the occurrence of the outcome in the intervention and the control group. It is unusual for the RR to be exactly 1.0, and understanding what it means if it is above or below this value depends on whether the outcome being counted is judged to be good or bad. </p> <p>If the RR is greater than 1.0, the intervention increases the risk of the outcome. If it is a good outcome (e.g. the birth of a healthy baby), an RR &gt; 1.0 indicates a desirable effect for the intervention, whereas if the outcome is bad (e.g. death), an RR &gt; 1.0 would indicate an undesirable effect. </p> <p>If the RR is less than 1.0, the intervention decreases the risk of the outcome. This indicates a desirable effect if it is a bad outcome (e.g. death) and an undesirable effect if it is a good outcome (e.g. birth of a healthy baby). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>What is the difference between absolute and relative effects?</b> </p> <p>The effect of an intervention can be described by comparing the risk of the intervention group with the risk of the control group. Such a comparison can be made in different ways. </p> <p>One way to compare two risks is to calculate the difference between the risks. This is the absolute effect. </p> <p>Consider the risk for blindness in a person with diabetes over a five‐year period. If the risk for blindness is found to be 20 in 1000 (2%) in a group of people treated conventionally and 10 in 1000 (1%) in people treated with a new drug, the absolute effect is derived by subtracting the intervention group risk from the control group risk: 2%/1% = 1%. Expressed in this way, it can be said that the new drug reduces the five‐year risk for blindness by 1% (absolute effect is 10 fewer per 1000). </p> <p>Another way to compare risks is to calculate the ratio of the two risks. Given the data above, the relative effect is derived by dividing the two risks, with the intervention risk being divided by the control risk: 1% ÷ 2% = ½ (0.50). Expressed in this way, as the 'relative effect', the five‐year risk for blindness with the new drug is 1/2 the risk with the conventional drug. </p> <p>Here the table presents risks as x per 1000 (or 100, etc.) instead of %, as this tends to be easier to understand. Whenever possible, the table presents the relative effect as the RR. </p> <p>Usually the absolute effect is different for groups that are at high and low risk, whereas the relative effect often is the same. Therefore, when it is relevant, we have reported indicative risks for groups at different levels of risk. Two or three indicative control group risks and the corresponding intervention group risks are presented when there are important differences across different populations. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean difference (MD) is the average difference between the intervention group and the control group across trials. Here a weighted MD is used, which means the results of some of the trials make a greater contribution to the average than others. Trials with more precise estimates for their results (narrower confidence intervals) are given more weight. </p> <p>This way of measuring effect is used when combining or comparing data for continuous outcomes, such as weight, blood pressure, or pain measured on a scale. When different scales are used to measure the same outcome, e.g. different pain scales, a standardised mean difference (SMD) may be provided. This is a weighted mean difference standardised across trials giving the average difference in standard deviations for the measures of that outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confidence interval</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A confidence interval (CI) is a range around an estimate that conveys how precise the estimate is; in this example the result is the estimate of the intervention group risk. The CI is a guide to how sure we can be about the quantity we are interested in (here the true absolute effect). The narrower the range between the two numbers, the more confident we can be about what the true value is; the wider the range, the less sure we can be. The width of the CI reflects the extent to which chance may be responsible for the observed estimate (with a wider interval reflecting more chance). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% confidence interval</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As explained above, the CI indicates the extent to which chance may be responsible for the observed numbers. In the simplest terms, a 95% CI means that we can be 95% confident that the true size of effect is between the lower and upper confidence limit (e.g. 0 and 3 in the blindness drugs example mentioned above). Conversely, there is a 5% chance that the true effect is outside of this range. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant means that a result is unlikely to have occurred by chance. The usual threshold for this judgement is that the results, or more extreme results, would occur by chance with a probability of less than 0.05 if the null hypothesis (no effect) were true. When results are not statistically significant, as in this example, this is stated to alert users to the possibility that the results may have occurred by chance. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants (trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The table provides the total number of participants across trials and the number of trials that provided data for that outcome. This indicates how much evidence there is for the outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty of the evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The certainty of the evidence is a judgement about the extent to which we can be confident that the estimates of effect are correct. These judgements are made using the GRADE system, and are provided for each outcome. The judgements are based on the type of study design (randomised trials versus observational trials), the risk of bias, the consistency of the results across trials, and the precision of the overall estimate across trials. </p> <p>For each outcome, the certainty of the evidence is rated as high, moderate, low, or very low using the following definitions: </p> <p> <ul id="CD011746-list-0018"> <li> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect </p> </li> <li> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> </li> <li> <p><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect </p> </li> <li> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A ‐ indicates that the information is not relevant.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Explanations for Cochrane 'Summary of findings' tables</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/full#CD011746-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gemcitabine plus vandetanib versus vandetanib alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 1 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 3 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade 1 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Grade 3 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gemcitabine plus vandetanib versus vandetanib alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Gemcitabine versus vandetanib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 1 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 3 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade 1 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Grade 3 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Gemcitabine versus vandetanib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gemcitabine plus cisplatin versus S‐1 plus cisplatin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 1 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 3 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade 1 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Grade 3 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Grade 1 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Grade 3 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gemcitabine plus cisplatin versus S‐1 plus cisplatin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Gemcitabine plus S‐1 versus S‐1</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.27, 4.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 1 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.00, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Grade 3 ‐ 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Grade 1 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.39, 4.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Grade 3 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Grade 1 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [1.04, 10.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Grade 3 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.32, 27.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Gemcitabine plus S‐1 versus S‐1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus best supportive care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus best supportive care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus fluorouracil plus folinic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 3 ‐ 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Gemcitabine plus oxaliplatin versus 5‐fluorouracil plus cisplatin plus radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011746-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality at one year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Grade 1 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Grade 3 ‐ 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Gemcitabine plus mitomycin C versus capecitabine plus mitomycin C</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011746.pub2/references#CD011746-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011746.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011746-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011746-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011746-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ro#CD011746-note-0015">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD011746-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011746-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011746\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011746\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011746\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011746\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011746\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011746.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011746.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011746.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011746.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011746.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728490659"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011746.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728490663"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011746.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5c0da139367',t:'MTc0MDcyODQ5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 